omeprazole has been researched along with rabeprazole in 518 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 62 (11.97) | 18.2507 |
| 2000's | 374 (72.20) | 29.6817 |
| 2010's | 57 (11.00) | 24.3611 |
| 2020's | 25 (4.83) | 2.80 |
| Authors | Studies |
|---|---|
| Bariwal, J; Bhosale, AV; Jagtap, JR; Jain, KS; Kale, AP; Shah, AK; Shelke, SM | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Castillo, R; Hernández-Campos, A; Hernández-Luis, F; Pérez-Villanueva, J; Romo-Mancillas, A; Yépez-Mulia, L | 1 |
| Burburan, PJ; Matubia, VN; Parkin, DW; Ramcharan, SS; Rosario, I; Shea, TA; Stockman, BJ | 1 |
| Fako, VE; Liu, JY; Pflug, B; Wu, X; Zhang, JT | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bi, Y; Kuberan, B; Might, M; Vankayalapati, H | 1 |
| Bala, V; Chhonker, YS | 1 |
| Beghyn, T; Bosc, D; Charton, J; Deprez, B; Deprez-Poulain, R; Guillaume, V; Herledan, A; Hermant, P; Landry, V; Leroux, F; Liang, W; Pottiez, V; Sheng, L; Tang, WJ; Urata, S; Warenghem, S | 1 |
| Chen, WL; Chen, X; Guo, XK; Jiang, ZY; Li, DD; Wang, YZ; Xu, JJ; You, QD | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Igata, H; Okabe, S | 1 |
| Harada, Y; Ikeda, H; Kawai, T; Saitou, T | 1 |
| Morii, M; Sakai, H; Takeguchi, N; Yamanouchi, T | 1 |
| Arisawa, T; Asai, J; Goto, H; Hase, S; Suzuki, T; Tsukamoto, Y | 1 |
| Fujimoto, M; Fujisaki, H; Murakami, M; Oketani, K; Sakai, H; Shibata, H; Takeguchi, N; Wakabayashi, T; Yamaguchi, M; Yamatsu, I | 1 |
| Goto, H; Hoshino, H; Kuroiwa, M; Nakazawa, S; Ohara, A; Ozawa, T; Sugiyama, S; Tsukamoto, Y | 1 |
| Fujisaki, H; Morii, M; Takata, H; Takeguchi, N | 1 |
| Azuma, T; Hirai, M; Ito, S; Kato, T; Kohli, Y | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| Hamatani, K; Morii, M; Takeguchi, N | 1 |
| Chiba, K; Horai, Y; Ishizaki, T; Kobayashi, K; Manabe, K; Nakai, H; Tomono, Y; Yamato, C; Yasuda, S | 1 |
| Chiba, K; Hayashi, M; Horai, Y; Ishizaki, T; Koyama, E; Manabe, K; Tomono, Y; Toyoki, T; Yamato, C; Yasuda, S | 1 |
| Morii, M; Takeguchi, N; Tomiyama, Y | 1 |
| Hasegawa, J; Morishita, N; Nakai, H; Ogawa, T; Ohnishi, A; Shimamura, Y; Tomono, Y; Yasuda, S | 1 |
| Kanazawa, T; Kayano, M; Nakai, H; Shimamura, Y; Yasuda, S | 1 |
| Aoki, T; Higashimoto, Y; Kanayama, S; Miwa, K; Miyazaki, I; Miyazaki, Y; Narita, T; Okuda, Y; Shinomura, Y; Yasunaga, Y | 1 |
| Fujimoto, M; Fujisaki, H; Murakami, M; Oketani, K; Shibata, H; Takeguchi, N; Wakabayashi, T; Yamatsu, I | 1 |
| Morii, M; Takeguchi, N | 1 |
| Imamura, L; Kobashi, K; Park, JB; Tsuchiya, M | 1 |
| Aoki, T; Fukui, H; Higashimoto, Y; Imamura, I; Miwa, K; Miyazaki, I; Miyazaki, Y; Narita, T; Okuda, Y; Shinomura, Y | 1 |
| Hayata, Y; Mizoguchi, K; Morii, M; Takeguchi, N | 1 |
| Binkley, SN; Ring, BJ; VandenBranden, M; Wrighton, SA | 1 |
| Imamura, L; Kobashi, K; Park, JB | 1 |
| Asakawa, N; Chiku, S; Mano, N; Nakata, H; Oda, Y; Takakuwa, S | 1 |
| Asakawa, N; Ebine, K; Kawakami, Y; Murahashi, M; Narukawa, M; Nochi, S; Sato, T; Yokoyama, Y | 1 |
| Asano, S; Morii, M; Takeguchi, N | 1 |
| Asakawa, N; Chiku, S; Mano, N; Nakata, H; Takakuwa, S; Yuzuriha, T | 1 |
| Hildebrandt, AG; Kleeberg, U; Krusekopf, S; Ruckpaul, K | 1 |
| Besancon, M; Sachs, G; Shin, JM; Simon, A | 1 |
| Greenwood, B; Humphries, TJ; Maton, PN; Robinson, M; Rodriguez, S | 1 |
| Andersson, K; Bayati, A; Lee, H; Lorentzon, P | 1 |
| Faulds, D; Prakash, A | 1 |
| Bassion, S; Cloud, ML; Enas, N; Humphries, TJ | 1 |
| Fujisaki, H; Nagakawa, J; Oketani, K; Takenaka, O; Yamanishi, Y | 1 |
| Barbuti, RC; Humphries, TJ; Kovacs, TO; Lew, EA; Sytnic, B; Walsh, JH | 1 |
| Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B | 3 |
| Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D | 1 |
| Hamilton, MI; Pounder, RE; Sercombe, J; Williams, MP | 1 |
| Asaki, S; Hongo, M; Kimpara, T; Moriyama, S; Ohara, S; Sone, S; Tamura, T; Toyota, T | 1 |
| Higashi, S; Kawaguchi, M; Murakami, M; Tomono, Y; Yasuda, S | 1 |
| Grimes, I; Hoyumpa, AM; Humphries, TJ; Trevino-Alanis, H | 1 |
| Hirai, S; Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Watanabe, S | 1 |
| Azuma, T; Dojyo, M; Ito, S; Ito, Y; Kato, T; Kohli, Y; Kuriyama, M; Miyaji, H; Suto, H; Yamazaki, Y | 1 |
| Burkhardt, F; Dammann, HG; Wolf, N | 1 |
| Grimes, I; Humphries, TJ; Keane, WF; Swan, SK | 1 |
| Humphries, TJ; Sachs, G | 1 |
| Pounder, RE; Williams, MP | 1 |
| Hoyumpa, AM; Merritt, GJ; Swan, SK | 1 |
| Humphries, TJ; Merritt, GJ | 1 |
| Horai, Y; Ishizaki, T | 1 |
| Langtry, HD; Markham, A | 1 |
| Miller, JL | 1 |
| Robinson, M | 4 |
| Lew, EA | 1 |
| Cockburn, I; Thjodleifsson, B | 1 |
| Barth, J; Humphries, TJ | 1 |
| Akahane, T; Gotoh, A; Katsuyama, T; Kawakami, Y; Oana, K; Okabe, T; Okimura, Y; Takahashi, Y; Yamaguchi, M | 1 |
| Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T | 1 |
| Maekawa, N; Mikawa, K; Nishina, K; Obara, H; Shiga, M; Takao, Y | 1 |
| Breiter, JR; Humphries, TJ; Riff, D | 1 |
| Maeyama, K; Matsui, H; Nakamura, S; Onji, M; Watanabe, H; Yokota, T | 1 |
| Beker, JA; Bjaaland, T; Dekkers, C; Finnegan, V; Humphries, TJ; Thjodleifsson, B | 1 |
| Hori, K; Hoshino, U; Kohno, M; Okumura, T; Yamada, M; Yoshimura, T | 1 |
| Blanshard, C; Millson, C; Pounder, RE; Sercombe, J; Williams, MP | 1 |
| Barbuti, RC; Humphries, TJ; Kovacs, TO; Ohning, GV; Sytnik, B; Walsh, JH | 1 |
| Iida, N; Kurosawa, A; Miwa, H; Nagahara, A; Ogawa, K; Ohkura, R; Sato, N | 1 |
| Arakawa, T; Fujiwara, Y; Higuchi, K; Tominaga, K; Watanabe, T | 1 |
| Barth, J; Johnson, D; Jokubaitis, L; Perdomo, C | 1 |
| Adachi, K; Amano, K; Katsube, T; Kawamura, A; Kinoshita, Y; Uchida, Y; Watanabe, M | 1 |
| Fukazawa, K; Ishino, Y; Kawakami, S; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Sugano, K | 1 |
| Farley, A; Humphries, TJ; Wruble, LD | 1 |
| Birbara, C; Breiter, J; Hahne, W; Perdomo, C | 1 |
| Shimizu, T; Tamura, Y; Taneike, I; Toyoda, S; Yamamoto, T; Yamashiro, Y | 1 |
| Adachi, K; Amano, K; Fukuda, R; Ishihara, S; Katsube, T; Kawamura, A; Kinoshita, Y; Takashima, T; Watanabe, M; Yuki, M | 1 |
| Arancio, F; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Cuoco, L; Gasbarrini, A; Gasbarrini, G; Pirozzi, G; Santarelli, L; Zocco, MA | 1 |
| Goshi, S; Iwakura, N; Kojio, S; Matsumaru, H; Ohara, T; Taneike, I; Tsutsui, N; Wakisaka-Saito, N; Yamamoto, T; Zhang, HM | 1 |
| Thomson, AB | 1 |
| Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C | 1 |
| Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Morikawa, T; Murase, K; Murata, I; Nishiyama, T; Omagari, K | 1 |
| Armuzzi, A; Bartolozzi, F; Cammarota, G; Canducci, F; Cremonini, F; Gasbarrini, A; Gasbarrini, G; Pola, P | 1 |
| Akagi, K; Hizawa, K; Inuzuka, S; Matsumoto, T; Nakahara, T; Yano, Y | 1 |
| Anti, M; Armuzzi, A; Bartolozzi, F; Cammarota, G; Candelli, M; Canducci, F; Cremonini, F; De Lorenzo , A; Gasbarrini, A; Gasbarrini, G; Ojetti, V; Pola, P | 1 |
| Larson, LR; Ofman, JJ; Siddique, RM; Willian, MK; Yamashita, BD | 1 |
| Gregor, JC | 1 |
| Humphries, TJ | 1 |
| Cohen, G; Delchier, JC; Humphries, TJ | 1 |
| Kurosawa, A; Miwa, H; Nagahara, A; Ohkura, R; Sato, N; Yamada, T | 1 |
| Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Okimoto, T; Satoh, R | 1 |
| Bardhan, KD; Barth, J; Lanza, F; Niecestro, R; Perdomo, C | 1 |
| Akamatsu, H; Mikawa, K; Nishina, K; Niwa, Y | 1 |
| Kölbel, CB; Lüth, S; Singer, MV; Teyssen, S | 1 |
| Furuie, H; Horai, Y; Irie, S; Ishizaki, T; Kimura, M; Koga, Y; Matsuguma, K; Matsui, T; Murakami, M; Nagahama, T; Urae, A; Yao, T | 1 |
| Bardou, M | 1 |
| Gerson, LB; Triadafilopoulos, G | 1 |
| Belafsky, PC; Koufman, JA; Postma, GN | 1 |
| Goshi, S; Ohara, T; Tamura, Y; Taneike, I; Yamamoto, T; Zhang, HM | 1 |
| Hojo, M; Miwa, H; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Yamada, T | 1 |
| Furuta, T; Hanai, H; Ishizaki, T; Nakagawa, K; Ohashi, K; Shirai, N; Sugimura, H; Takashima, M; Xiao, F | 1 |
| Berger, C; Fleckman, P; Johnstone, D | 1 |
| Ishiki, K; Maga, T; Miyoshi, M; Mizuno, M; Nagahara, Y; Nasu, J; Oguma, K; Okada, H; Torigoe, T; Tsuji, T; Yokota, K | 1 |
| Bhattacharjya, AS; Dean, BB; Ofman, JJ; Siddique, RM; Yamashita, BD | 1 |
| Aoyama, N; Hohda, T; Kasuga, M; Kita, T; Nishiguchi, K; Nishitora, Y; Okumura, K; Sakaeda, T; Sakai, T; Sirasaka, D; Tamura, T; Tanigawara, Y | 1 |
| Sheptulin, AA | 2 |
| Caro, JJ; Salas, M; Ward, A | 1 |
| Baranskaia, EK | 1 |
| Avasthy, N; Ducrottè, P; Fournet, J; Galmiche, JP; Humphries, TJ; Rampal, P; Zerbib, F | 1 |
| Asaka, M; Hige, S; Hokari, K; Ishizuka, J; Kagaya, H; Kato, M; Komatsu, Y; Kudo, M; Miyagishima, T; Mizushima, T; Nishikawa, K; Saito, M; Sugiyama, T; Takeda, H | 1 |
| Golochalova, TV; Gorbakov, VV; Makarov, IuS; Mironenko, DA; Rakov, AL | 1 |
| Herszényi, L; Tulassay, Z | 1 |
| Fukushima, Y; Hasegawa, J; Ieiri, I; Ishizaki, T; Kishimoto, Y; Kitano, M; Momiyama, K; Morisawa, T; Morita, T; Nakagawa, K; Okochi, H; Otsubo, K | 1 |
| Esaki, M; Fukuda, T; Kurahara, K; Kusano, Y; Matsumoto, T; Nakamura, S | 1 |
| Barnett, JL; Robinson, M | 1 |
| Chiba, K; Furuta, T; Hanai, H; Ishizaki, T; Kobayashi, K; Kosuge, K; Moriyama, Y; Nakagawa, K; Ohashi, K; Okochi, H; Shirai, N; Takashima, M; Xiao, F | 1 |
| Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF | 1 |
| Starostin, BD | 2 |
| Kromer, W | 1 |
| Carswell, CI; Goa, KL | 1 |
| Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Saito, T | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Fukao, K; Homma, M; Itagaki, F; Kohda, Y; Yuzawa, K | 2 |
| Andrade, RJ; Lucena, MI | 1 |
| Hassan, C; Lorenzetti, R; Morini, S; Zullo, A | 1 |
| Barth, J; Hahne, W | 1 |
| Ishii, H; Kitahora, T; Miyazawa, M; Nagahashi, S; Suzuki, H; Suzuki, K; Suzuki, M | 1 |
| Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M | 1 |
| Barth, JA; Gardner, JD; Hahne, WF; Perdomo, C; Robinson, M; Rodriguez-Stanley, S; Sloan, S | 1 |
| Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M | 1 |
| Louis, E | 1 |
| Haruma, K; Kajiyama, G; Kawano, M; Kodama, K; Okahara, S; Sumii, K; Tari, A; Yonei, Y | 1 |
| Sugano, K | 1 |
| Hurwitz, A; Parsonnet, J; Passaro, DJ; Triadafilopoulos, G | 1 |
| Fu, HY; Kawano, S; Tanimura, H | 1 |
| Ohkusa, T; Sato, N | 1 |
| Furuta, T; Shirai, N | 1 |
| Takahashi, S; Tokunaga, K | 1 |
| Ishitobi, H; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Kuwayama, H; Takahashi, M | 1 |
| Yoshino, J | 1 |
| Adachi, K; Kinoshita, Y | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 2 |
| Ivanova, NG | 1 |
| Chaplygin, NV; Lipatova, TE; Osadchuk, MA | 2 |
| Kheĭlyk, AI; Kulidzhanov, AIu; Kvetnoĭ, IM; Osadchuk, MA; Usik, SF | 1 |
| Abe, K; Adachi, K; Hamamoto, N; Ishihara, S; Kawashima, K; Kawauchi, H; Kinoshita, Y; Mak, R; Moritani, M; Oshima, N; Sato, H | 1 |
| Mikawa, K; Morikawa, O; Nishina, K; Obara, H; Takao, Y; Uesugi, T | 1 |
| Filippone, J; Jokubaitis, L; Miner, P; Orr, W; Sloan, S | 1 |
| Inaba, T; Kawai, K; Miyoshi, M; Mizuno, M; Oguma, K; Okada, H; Take, S; Tsuji, T; Yokota, K | 1 |
| Adler, E; Bhattacharyja, A; Damiano, A; Handley, K; Siddique, R | 1 |
| Tahboub, RM; Vanderhoff, BT | 1 |
| Dodd, S; Durkin, M; Hall, J; Sloan, S | 1 |
| Guilford, S; Johnson, M; Libretto, SE | 1 |
| Asano, T; Fukushima, Y; Hirakawa, J; Ishikawa, T; Katsube, T; Mori, H; Ogawa, K; Ohkawa, S; Otsuka, H; Saitoh, T | 1 |
| Noskova, KK; Vasil'ev, IuV; Zelenikin, SA | 1 |
| Kas'ianenko, VI; Vasil'ev, IuV | 1 |
| Aronova, OV; Minushkin, ON; Shuleshova, AG; Zverkov, IV | 1 |
| Fuhr, U; Jetter, A | 1 |
| De Francesco, V; Faleo, D; Ierardi, E; Margiotta, M; Panella, C | 1 |
| Abe, H; Arita, T; Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S | 1 |
| Sachs, G; Shin, JM | 1 |
| Handa, Y; Kawai, T; Kawakami, K; Kudo, T; Moriyasu, F; Ogiahara, S | 1 |
| Lin, S | 1 |
| Frissora, C; Katz, PO | 1 |
| Bhattacharjya, A; Damiano, AM; Johanson, JF; Jokubaitis, L; Murthy, A; Siddique, R | 1 |
| Golochalova, TV; Kashchenko, OI; Lezhenina, NP; Makarov, IuS; Nemytin, IuV; Pavlov, AI | 1 |
| Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C | 1 |
| Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Arutiunov, AG; Burdina, EG; Burkov, SG; Svirchev, VV | 1 |
| Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H | 1 |
| Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM | 1 |
| Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B | 1 |
| El-Gindy, A; El-Yazby, F; Maher, MM | 1 |
| Aoyama, N; Baba, T; Kakumoto, M; Kasuga, M; Kawahara, Y; Kirita, S; Kita, T; Kurimoto, Y; Okamura, N; Okumura, K; Sakaeda, T | 1 |
| Butenko, EV; Pakhomova, IG; Ratnikov, VA; Sablin, OA | 1 |
| Chan, CK; Fung, FM; Gu, Q; Hu, WH; Lai, KC; Lam, SK; Wong, BC; Wong, WM; Xia, HH; Yee, YK; Yuen, MF | 1 |
| Calvet, X; Gisbert, JP; Khorrami, S; Pajares, JM | 1 |
| Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP | 1 |
| Campo, SM; De Francesco, V; Faleo, D; Fornari, F; Gatta, L; Hassan, C; Ierardi, E; Marinone, G; Menegatti, M; Merla, A; Mete, LS; Miglioli, M; Morini, S; Papadìa, C; Perna, F; Perri, F; Pilati, S; Potì, R; Ricci, C; Rinaldi, V; Savioli, A; Tampieri, A; Vaira, D; Vakil, N; Zullo, A | 1 |
| Durham, S; McElhinney, C; Sarosiek, I; Sarosiek, J; Skoczylas, T; Sostarich, S | 1 |
| Sloan, S | 1 |
| Ebert, CC; Jones, MP; Shah, D | 1 |
| Gardner, JD; Miner, PB; Robinson, M; Sloan, S | 4 |
| Kleeberg, U; Krusekopf, S; Roots, I | 1 |
| Atherton, JC; Hawkey, CJ; Ravic, M; Thjodleifsson, B; Treichel, HC | 1 |
| Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X | 1 |
| Barth, J; Kovacs, TO; Murthy, A; Ohning, GV; Pisegna, JR; Walsh, JH | 1 |
| Ashida, S; Fujiki, S; Hosaki, Y; Mitsunobu, F; Mizuno, M; Okada, H; Okamoto, M; Shiratori, Y; Tanizaki, Y; Tsugeno, H | 1 |
| Aragona, G; Cavestro, GM; Dal Bo, N; Franceschi, M; Franze, A; Iori, V; Leandro, G; Mario, FD; Moussa, AM; Pilotto, A; Rugge, M | 1 |
| Bessho, M; Ishii, H; Miura, S; Miyazawa, M; Nagahashi, S; Nagata, H; Sato, M; Suzuki, H | 1 |
| Angeletti, S; De Francesco, V; Hassan, C; Ierardi, E; Lorenzetti, R; Marignani, M; Morini, S; Zullo, A | 1 |
| Chern, HD; Lin, CJ; Uang, YS; Wang, TH; Yang, JC | 1 |
| Blum, AL; Dorta, G; Jornod, P; Pantoflickova, D; Ravic, M | 1 |
| Enjoji, A; Fujimoto, C; Furusu, H; Hirakata, Y; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Murase, K; Murata, I; Omagari, K; Shimada, S; Yamakawa, M | 1 |
| Jansen, JB; Laheij, RJ; Van Rossum, LG; Verheugt, FW | 1 |
| Hellström, PM; Vitols, S | 1 |
| Bikbulatova, EA; Osipenko, MF; Pankova, LIu | 1 |
| Delattre, M; Felicio, L; Le, GH; Morreale, AP; Okino, L; Plowman, BK; Schaefer, MG | 1 |
| Abe, Y; Chiguchi, G; Fujisawa, N; Inamori, M; Iwasaki, T; Kawamura, H; Kikuchi, T; Kirikoshi, H; Kobayashi, N; Matsumoto, S; Muramatsu, K; Nakajima, A; Ozawa, Y; Sakaguchi, T; Sekihara, H; Takahashi, K; Takamura, T; Togawa, J; Ueno, N; Yoneda, M | 1 |
| Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L | 1 |
| Adami, M; Brenciaglia, MI; Cena, C; Coruzzi, G; Dubini, F; Fruttero, R; Galli, U; Gasco, A; Morini, G; Sorba, G | 1 |
| De Francesco, V; Hassan, C; Ierardi, E; Morini, S; Panella, C; Piglionica, D; Scaccianoce, G; Zullo, A | 1 |
| Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY | 1 |
| Adachi, K; Amano, Y; Fujishiro, H; Karim Rumi, MA; Kawamura, A; Kinoshita, Y; Komazawa, Y; Mihara, T; Ono, M; Yuki, M | 1 |
| Balashova, NN; Busarova, GA; Maev, IV | 1 |
| Gong, J; Luo, JY; Niu, CY; Wang, XQ; Zhu, YL | 1 |
| McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I | 1 |
| Gallo-Torres, H; Gardner, JD; Miner, PB; Robinson, M; Sloan, S | 1 |
| Atisook, K; Kachintorn, U; Kositchaiwat, C; Ovartlarnporn, B | 1 |
| Ashman, O; Borody, TJ | 1 |
| Aragona, G; Cavallaro, L; Cavestro, GM; Comparato, G; Dal Bò, N; Di Mario, F; Franzè, A; Iori, V; Leandro, G; Pilotto, A | 1 |
| Danilin, MS; Kucheriavyĭ, IuA; Maev, IV | 1 |
| Starostin, BD; Starostina, GA | 1 |
| Dai, SJ; Li, YY; Nie, YQ; She, QZ; Wang, H | 1 |
| Inaba, T; Ishiki, K; Mizuno, M; Nagahara, Y; Oguma, K; Okada, H; Shiratori, Y; Take, S; Yamamoto, K; Yokota, K; Yoshida, T | 1 |
| Maeyama, K; Matsui, H; Matsuura, B; Onji, M; Yokota, T | 1 |
| Moldenhauer, ET | 1 |
| Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
| Araki, Y; Fujii, A; Katayama, A; Miyawaki, S; Takano-Yamamoto, T; Tanimoto, Y | 1 |
| Ivashkin, VT; Trukhmanov, AS | 1 |
| Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P | 1 |
| Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S | 1 |
| Thjodleifsson, B | 1 |
| Horikawa, Y; Inoue, M; Kuroiwa, T; Shimatani, T | 1 |
| Chen, Y; Katz, PO; Miner, P; Sostek, M | 1 |
| Bae, JS; Jung, HS; Kim, HJ; Lee, JK; Lee, SB; Park, SJ; Park, SM; Ryu, JK | 1 |
| Augustyńska, B; Budzyński, J; Fabisiak, J; Grad, K; Kłopocka, M; Pulkowski, G; Suppan, K; Swiatkowski, M | 1 |
| Branca, G; Cammarota, G; Cannizzaro, O; Cesaro, P; Cianci, R; di Caro, S; Fedeli, P; Gasbarrini, G; Lecca, PG; Martino, A | 1 |
| Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I | 1 |
| Barone, M; Berloco, P; Burattini, O; De Francesco, V; Di Leo, A; Francavilla, A; Ierardi, E; Marangi, S; Margiotta, M; Minenna, MF; Morini, S; Panella, C; Russo, F; Stoppino, V; Zullo, A | 1 |
| Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC | 1 |
| Hao, YT; He, XX; Zhao, YH | 1 |
| Klochko, OG; Kornienko, EA | 1 |
| Cammarota, G; Candelli, M; Crea, F; Gasbarrini, A; Gasbarrini, G; Marietti, G; Nista, EC; Petrucci, S; Pignataro, G; Rigante, D; Schiavino, A | 1 |
| Alfonzo, CA; Almond, MD; Bobo, WV | 1 |
| Amoruso, A; De Francesco, V; Della Valle, N; Ierardi, E; Muscatiello, N; Panella, C; Stoppino, V | 1 |
| Casey, JF; Clark, GW; Guillou, PJ; Hick, DG; Sarela, AI; Verbeke, CS | 1 |
| Jansen, JB; Laheij, RJ; van Rossum, LG; Verheugt, FW; Vlemmix, F | 1 |
| Araj, GF; Barada, KA; Chaar, HF; Moukhachen, O; Mourad, FH; Racoubian, E; Sharara, AI | 1 |
| De Francesco, V; Della Valle, N; Hassan, C; Ierardi, E; Minenna, MF; Monno, R; Morini, S; Panella, C; Pietrini, L; Stoppino, V; Winn, S; Zullo, A | 1 |
| Banerjee, SN; Chattaraj, TK; Ganesan, M; Jayakumar, M; Mondal, U; Pal, TK; Roy, K | 1 |
| Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Shiba, M; Tominaga, K; Watanabe, T | 1 |
| Barth, J; Lanza, F; Schwartz, H; Vakil, N | 1 |
| Abd El-Ghany, N; Radi, A; Wahdan, T | 1 |
| Blum, A; Bytzer, P; De Herdt, D; Dubois, D | 1 |
| Abudayyeh, S; Belson, G; Dore, MP; El-Zimaity, HM; Graham, DY; Osato, MS | 1 |
| de Korwin, JD; Ducrotté, P; Vallot, T | 1 |
| Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L | 1 |
| Homma, M; Itagaki, F; Kohda, Y; Naito, S; Nishimura, M; Ohkohchi, N; Ueda, N; Yuzawa, K | 1 |
| Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ | 1 |
| Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M | 1 |
| Goh, KL; Lim, PW | 1 |
| Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Morawski, W; Pulkowski, G; Suppan, K; Swiatkowski, M | 1 |
| Takeda, H | 1 |
| Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T | 1 |
| Hoshino, E; Ishiyama, A; Tsuchida, T | 1 |
| Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Alonso, C; Bernal, JL; del Nozal, MJ; Jiménez, JJ; Toribio, L | 1 |
| Blancas-Valencia, JM; Bosques-Padilla, FJ; Calderón-Lozano, IE; de Ariño Suárez, M; Garza-González, E; Orozco-Gámiz, A; Reed-SanRoman, G; Tamayo-de la Cuesta, JL; Valdovinos-Díaz, MA | 1 |
| Bae, HM; Hong, SP; Hwang, SG; Kim, JW; Kim, KC; Kim, KH; Kim, SH; Ko, KH; Kwak, SY; Kwon, KS; Na, SH; Park, MJ; Park, PW; Park, SJ; Ryu, JK; Ryu, KH; Shin, YW; Won, WH; Woo, YK; Yoo, HM | 1 |
| Kotaira, J | 1 |
| Budzyński, J; Kłopocka, M; Pulkowski, G; Sinkiewicz, A; Swiatkowski, M | 1 |
| Babaian, ML; Khanakaeva, ZK; Khavkin, AI; Rachkova, NS; Volynets, GV; Zhikhareva, NS | 1 |
| Homma, M; Itagaki, F; Kobayashi, H; Kohda, Y; Ohnishi, N; Okamura, N; Sakaeda, T; Takara, K; Yagami, T; Yokoyama, T | 1 |
| Kelly, DH; Long, JD; Patil, MS; Schwartzbauer, HR; Steward, DL; Welge, JA; Wilson, KM | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Ohashi, K; Sakurai, M; Shirai, N; Sugimoto, M | 1 |
| Bicheler, V; Bonaz, B; Bonnot-Marlier, S; Bost, R; Bruley des Varannes, S; Delchier, JC; Gharib, H; Stanescu, L | 1 |
| Horn, J | 1 |
| Miner, P | 1 |
| Ke, MY | 1 |
| Hellström, PM | 1 |
| Gupta, S; Jain, M; Lohray, BB; Shah, H; Shah, R; Singh, SS; Thakker, P | 1 |
| Vasil'ev, IuB | 1 |
| Anikina, NIu; Maslovskiĭ, LV; Minushkin, ON | 1 |
| Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
| Kononov, AV; Livzan, MA | 1 |
| Cammarota, G; Candelli, M; Cazzato, IA; Cremonini, F; Franceschi, F; Gasbarrini, A; Gasbarrini, G; Nista, EC; Zocco, MA | 1 |
| Katz, PO | 1 |
| Koteshwara, M; Kumar, SS; Ramakrishna, NV; Vishwottam, KN; Wishu, S | 1 |
| Goodrich, S; Orr, WC; Robert, J | 1 |
| Imase, K; Ishida, H; Itoh, T; Kai, A; Sugano, H; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
| Pauly, MV; Wang, YR | 1 |
| Bosques-Padilla, FJ; Garza-González, E; Pérez-Pérez, GI; Tijerina-Menchaca, R | 1 |
| Hasegawa, J; Humphries, T; Laurent, A; Setoyama, T | 1 |
| Coleman, PL; Geevasinga, N; Roger, SD | 1 |
| Collins, N; Lobo, MM; Mat Saad, AZ; O'Connor, HJ | 1 |
| Hu, YM; Mei, Q; Xu, JM; Xu, SY; Xu, XH | 1 |
| Furukawa, H; Hata, M; Hattori, T; Iida, M; Negishi, N; Sekino, H; Sezai, A; Sezai, Y; Shiono, M; Soeda, M; Taoka, M; Wakui, S; Yoshitake, I | 1 |
| Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC | 1 |
| Brotze, S; Connor, M; Jaworski, T; Roeser, K; Sarosiek, I; Sarosiek, J; Sostarich, S; Wallner, G | 1 |
| Gadzhieva, MG; Maev, IV | 1 |
| Castro, LP; Cerqueira, MC; Cindr, JM; Coelho, LG; Gallo, MA; Mendonça, S; Moretzsohn, LD; Passos, MC; Pedrazzoli-Júnior, J; Ribeiro, ML; Vieira, WL; Vitiello, L | 1 |
| Fujimura, M; Hara, J; Katayama, N; Kita, T; Myou, S; Nakao, S; Nishitsuji, M; Oribe, Y | 1 |
| Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY | 1 |
| Chen, CB; Chou, JW; Hsu, CH; Lai, HC; Liao, KF; Lin, ZY; Wang, HH | 1 |
| Bonnot-Marlier, S; Bour, B; Chousterman, M; Labayle, D; Nalet, B; Nouel, O; Pariente, A; Staub, JL; Tocque, E | 1 |
| Gushchin, AE; Isakov, VA; Morozov, SV; Shipulin, GA; Tereshchenko, SG; Tsodikova, OM | 1 |
| Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B | 1 |
| Barry, M; Bennett, K; McGowan, B; Tilson, L | 1 |
| Accornero, L; Dulbecco, P; Savarino, E; Savarino, V; Zentilin, P | 1 |
| Archimandritis, AJ; Avgerinos, A; Kouklakis, G; Nikolopoulou, V; Paraskevas, E; Triantafillidis, JK; Tsianos, E | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Nakamura, A; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
| Han, SY; Jee, SR; Kim, DH; Lee, JT; Park, SJ; Seol, SY; Urm, SH | 1 |
| Oh, DS; Ohning, GV; Pisegna, JR | 1 |
| Gerson, LB; Shetler, K; Triadafilopoulos, G | 1 |
| Lin, SR | 1 |
| Anikina, NIu; Maslovskiĭ, LV; Minushkin, ON; Shuleshova, AG | 1 |
| Doma, S; Fisher, RS; Parkman, HP; Simonian, HP; Vo, L | 1 |
| Abe, Y; Chiguchi, G; Inamori, M; Iwasaki, T; Kawamura, H; Kikuchi, T; Kirikoshi, H; Kobayashi, N; Kubota, K; Matsumoto, S; Muramatsu, K; Nakajima, A; Ozawa, Y; Saito, S; Sakaguchi, T; Shimamura, T; Togawa, J; Ueno, N | 1 |
| Kawano, S; Tsuji, S | 1 |
| Chan, AO; Chan, CK; Cheung, KL; Fung, FM; Ho, VY; Huang, J; Hui, CK; Lai, KC; Lam, SK; Tong, TS; Wong, BC; Wong, WM; Xia, HH | 1 |
| Bernabucci, V; Cavina, M; De Francesco, V; Gatta, L; Hassan, C; Ierardi, E; Morini, S; Ricci, C; Vaira, D; Zullo, A | 1 |
| Alvarado, M; Hernández, J; Jiménez, S; Porcel, S; Rodríguez, A | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Habuchi, T; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Gao, S; Guo, Q; Huang, J; Rui, L; Xu, Y | 1 |
| Isaev, VA | 1 |
| Annese, V; Bianchi Porro, G; Casalini, S; Nardini, P; Pace, F; Prada, A; Zambelli, A | 1 |
| Horikawa, Y; Inoue, M; Kuroiwa, T; Nakamura, M; Shimatani, T; Tazuma, S; Xu, J | 1 |
| Botta, F; Fumagalli, A; Giannini, EG; Malfatti, F; Mamone, M; Polegato, S; Savarino, V; Testa, E; Testa, R | 1 |
| Akimoto, M; Hashimoto, H; Maeda, A; Shigemoto, M; Yamashita, K | 1 |
| Bory, F; Bujanda, L; Calvet, X; Ducons, J; Gisbert, JP; Montserrat, A | 1 |
| Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N | 2 |
| Barth, J; Breiter, J; Caos, A; Perdomo, C | 1 |
| Ando, T; Hongo, H; Ishizaki, T; Isozaki, Y; Kajikawa, H; Kato, H; Nagao, Y; Naito, Y; Seto, N; Shimozawa, M; Sugimoto, N; Yoshida, N; Yoshikawa, T | 1 |
| Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J | 1 |
| Anjiki, H; Kuyama, Y; Sanaka, M | 1 |
| Hall, M; Higbee, A; Mathur, S; Sampliner, RE; Sharma, P; Wani, S; Weston, AP | 1 |
| Danjo, A; Fujimoto, K; Hara, M; Iwakiri, R; Kikkawa, A; Oda, K; Ootani, A; Sakata, H; Shimoda, R; Tsunada, S; Watanabe, K | 1 |
| Hashimoto, H; Hirota, K; Kudo, M; Kushikata, T | 1 |
| Brown, RE; Remák, E; Robinson, A; Yuen, C | 1 |
| Johanson, J; Jokubaitis, L; Kahrilas, PJ; Mao, L; Miner, P; Sloan, S | 1 |
| Dodd, SL; Flood, E; Howell, J; Shikiar, R; Siddique, R | 1 |
| Bektaş, M; Cetinkaya, H; Ozden, A; Soykan, I; Törüner, M | 1 |
| Hirano, I; Kahrilas, PJ; Pandolfino, JE; Zhang, Q | 1 |
| Cartledge, J; Eastone, JA; Foggy, JR; Horwhat, JD; Johnston, MH; Mathews, JS | 1 |
| Sharara, AI | 1 |
| Hou, XH; Ke, MY; Liu, XH; Luo, JY; Song, ZQ; Sun, J; Yuan, YZ; Zha, H; Zhu, YL | 1 |
| Boluggdu, VB; Ganta, MR; Ghanta, MR; Jambula, MR; Pingili, RR; Sajja, E; Sundaram, V | 1 |
| Calvet, X; Gomollón, F | 1 |
| Park, SH | 1 |
| Goh, KL; Lim, PW; Wong, BC | 1 |
| Fujioka, T | 1 |
| Furuta, T; Nakmura, A; Shirai, N; Sugimoto, M | 1 |
| Fujioka, T; Murakami, K; Okimoto, T | 1 |
| Furuta, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Asaka, M; Kato, M; Nakagawa, M; Nakagawa, S; Shimizu, Y | 1 |
| Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R | 2 |
| Campos, A; Cardenas, VM; Chavez, A; El-Zimaity, HM; Graham, DY; Guerrero, L; Opekun, AR | 1 |
| Gao, N; Guo, YZ; Hu, YR; Jia, LJ; Qiao, HL; Tian, X; Zhang, LR | 1 |
| Barer, GM; Burkov, SG; Busarova, GA; Gurenev, GL; Maev, IV; Polikanova, EN; Pustovoĭt, EV | 1 |
| Inoue, M; Kuroiwa, T; Mieno, H; Nakamura, M; Shimatani, T; Tazuma, S; Xu, J | 1 |
| Burattini, O; De Francesco, V; Di Leo, A; Hassan, C; Ierardi, E; Marangi, S; Margiotta, M; Monno, R; Morini, S; Panella, C; Russo, F; Stella, F; Stoppino, V; Troiani, L; Zullo, A | 1 |
| Baek, JT; Chung, IK; Jeong, HY; Kim, AN; Kim, SH; Kim, SJ; Lee, BS; Lee, DS; Lee, GS; Lee, JM; Lee, SH; Lee, TY; Nam, SW; Oh, JI; Shin, JE; Sung, JK; Yoon, SJ | 1 |
| Furukawa, H; Hata, M; Hattori, T; Iida, M; Negishi, N; Sekino, H; Sezai, A; Sezai, Y; Shiono, M; Taoka, M; Wakui, S; Yoshitake, I | 1 |
| Abe, T; Arita, T; Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S; Watanabe, K | 1 |
| Hirakawa, K; Ishikawa, T; Katsuragi, K; Maeda, K; Mino, A; Ohira, M; Onoda, N; Sawada, T; Wakasa, K | 1 |
| Gardner, JD; Miner, PB; Robinson, M; Sloan, S; Young, W | 1 |
| DeVault, KR | 1 |
| Kagaya, H; Miura, M; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Barry, M; Bennett, K; Keeling, PW; O'Morain, C; Walshe, V | 1 |
| Garcia, CV; Paim, CS; Schapoval, EE; Steppe, M | 1 |
| Cubero, AG; González Sánchez, LA; Mosquera, MR; Pérez Pimiento, AJ; Prieto Lastra, L; Rodríguez Cabreros, MI | 1 |
| Crum, NF; Furtek, KJ; Olson, PE; Wallace, MR | 1 |
| Avorn, J; Canning, C; Dormuth, CR; Glynn, RJ; Maclure, M; Schneeweiss, S | 1 |
| Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP | 1 |
| Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F | 1 |
| Khalife, W; Mahmoud, F; Murunga, E | 1 |
| Miura, M | 1 |
| Clark, DW; Strandell, J | 1 |
| Ma, J; Mabasa, VH | 1 |
| Hunt, RH; Padol, IT; Padol, S; Thabane, M; Yuan, Y | 1 |
| Abdul-Baki, H; Aoun, E; Araj, GF; Chaar, HF; Kanj, SS; Sharara, AI | 1 |
| Gon, S; Irie, Y; Takahashi, M | 1 |
| Baik, SK; Jee, MK; Ji, S; Kim, HS; Kim, JW; Kwon, SO; Lee, DK; Park, KW; Song, JS; Uh, Y | 1 |
| Edwards, SJ; Lind, T; Lundell, L | 1 |
| Giannini, EG; Savarino, V; Testa, R | 1 |
| Hu, NZ; Hu, XP; Hu, YM; Mei, Q; Xu, JM; Xu, XH | 1 |
| Bytzer, P; Kennerly, P; Miller, N; Morocutti, A; Ravic, M | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Wertheimer, AI; Wilson, JM | 1 |
| Andersson, S; Nelander, H; Ohlén, K | 1 |
| Forrester, MB | 1 |
| Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H | 1 |
| Molnar, B; Mullner, K; Tulassay, Z | 1 |
| Beketov, AS; Belousov, DIu; Belousov, IuB; Karpov, OI | 1 |
| Burkov, SG; Iurenev, GL; Maev, IV; V'iuchnova, ES | 1 |
| Aoki, T; Itoi, T; Kawai, T; Kawakami, K; Matsumoto, Y; Mikinori, K; Moriyasu, F; Noguchi, N; Rimbara, E; Sasatsu, M; Takagi, Y; Takei, K; Watanebe, K | 1 |
| Serebrova, SIu | 1 |
| Boyer, K; Tolia, V | 1 |
| Mahachai, V; Thong-Ngam, D | 1 |
| Andriulli, A; Annese, V; D'Ambrosio, LP; Di Mario, F; Franceschi, M; Leandro, G; Paris, F; Pilotto, A; Scarcelli, C; Seripa, D | 1 |
| Furuta, T; Ishizaki, T; Shirai, N; Sugimoto, M | 1 |
| Ando, T; Ishikawa, T; Kokura, S; Naito, Y; Yoshida, N; Yoshikawa, T | 1 |
| Cho, YK; Choi, HS; Hwang, SJ; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JS; Sohn, CI | 1 |
| Fukuhara, Y; Inui, K; Ito, N; Katsura, T; Ogawa, O; Takahashi, K; Takahashi, T; Yamamoto, S; Yano, I | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Okimoto, T; Sato, R; Watanabe, K | 1 |
| Pai, N; Pai, V | 1 |
| Abdallah, M; Barada, K; Dakik, HA; Karrowni, W; Shamseddeen, W; Sharara, AI | 1 |
| Andersson, T; Weidolf, L | 1 |
| Giannoulis, E; Karamanolis, G; Ladas, SD; Theofanidou, I; Triantafyllou, K; Yiasemidou, M | 1 |
| Gardner, JD; Gerson, LB; Miner, PB; Robinson, M; Sahbaie, P; Sloan, S; Triadafilopoulos, G; Young, W | 1 |
| Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S | 1 |
| Garrean, CP; Gonsalves, N; Hirano, I; Zhang, Q | 1 |
| Gursoy, O; Memiş, D; Sut, N | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Huang, Z; Shi, R; Wang, J; Wang, X; Xu, Z; Yang, Y; Zhang, G; Zhao, F | 1 |
| Pellicano, R | 1 |
| Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K | 1 |
| Friesen, MH | 1 |
| DAS, R; Edwards, SJ; Lind, T; Lundell, L | 1 |
| Tan, VP; Wong, BC | 1 |
| Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA | 1 |
| Kume, K; Nagato, M; Otsuki, M; Yamasaki, M; Yoshikawa, I | 1 |
| Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y | 1 |
| Keyhanfar, F; Mahmoudian, M; Motevalian, M; Noubarani, M | 1 |
| Bottheim, H; Gross, M; Holinski-Feder, E; Kenngott, S; Kollmer, M; Laner, A; Olze, R | 1 |
| Nathisuwan, S; Panomvana, D; Sansanayudh, N; Siriswangvat, S | 1 |
| El-Tantawy, AS; Khalil, SM; Mohamed, GG; Nour El-Dien, FA | 1 |
| Hu, YM; Li, QS; Mei, Q; Xu, JM; Zhang, L | 1 |
| Guo, X; Ji, P; Lin, L; Ma, Z; Zhang, L | 1 |
| Niioka, T | 1 |
| Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Namiki, N; Nishino, M; Sugimoto, M; Uchida, S; Watanabe, H; Yamade, M | 1 |
| Howden, CW; Hughes, N; Kahrilas, PJ | 1 |
| Hofmann, U; Nies, AT; Resch, C; Rius, M; Schaeffeler, E; Schwab, M | 1 |
| Itoh, F; Kinoshita, Y; Kobayashi, S; Kumai, T; Matsumoto, N; Ohba, K; Suzuki, S; Takeba, Y; Watanabe, M; Yoshida, Y | 1 |
| Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J | 1 |
| Horiuchi, H; Ikeda, T; Imai, M; Jinnai, T; Kato, Y; Kimura, T; Makiyama, T; Shirakawa, R; Tada, T; Tazaki, J; Yamane, K | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Kawahara, K; Moroga, T; Okamura, Y; Takahashi, Y; Takeno, S; Yamashita, S | 1 |
| Fujimura, T; Fujita, H; Fushida, S; Harmon, JW; Hayashi, H; Kitagawa, H; Makino, I; Marti, GP; Matsui, D; Miyashita, T; Murakami, M; Nakagawara, H; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Shah, FA; Tajima, H; Takamura, H | 1 |
| Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Bhushan, R; Dixit, S; Dubey, R | 1 |
| Metz, DC; Shah, P; Singh, MH; Yang, YX | 1 |
| Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M | 1 |
| Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C | 1 |
| Azizi, M; Ducint, D; Funck-Brentano, C; Gaussem, P; Molimard, M; Remones, V; Steichen, O; Szymezak, J | 1 |
| Akiyama, J; Haruma, K; Inoue, K; Kamada, T; Konuma, I; Mabe, K; Miyamoto, M; Nagahara, A; Nagata, N; Sakurai, K; Sugai, N; Suzuki, T; Takeuchi, Y | 1 |
| Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Jung, YS; Kim, ES; Kim, EY; Kim, KO; Kim, WJ; Kwon, JG; Lee, SH; Oh, MJ; Park, CS; Park, KS; Yang, CH | 1 |
| Furuta, T; Ichikawa, H; Kagami, T; Kodaira, C; Nishino, M; Sahara, S; Shirai, N; Sugimoto, K; Sugimoto, M; Uotani, T | 1 |
| Belhocine, K; Bruley des Varannes, S; Flet, L; Touchefeu, Y; Vavasseur, F; Volteau, C | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Abad-Santos, F; Cabaleiro, T; Ochoa, D; Prieto-Pérez, R; Rivas, Â; Román, M; Sánchez-Rojas, SD; Talegón, M | 1 |
| Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
| Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
| Edogawa, S; Harada, S; Hayashi, K; Higuchi, K; Hongoh, Y; Hoshimoto, M; Itabashi, T; Kitae, H; Kojima, Y; Oota, K; Sakaguchi, M; Sanomura, M; Takeuchi, N; Takeuchi, T | 1 |
| Akers, KS; Boyd, NK; Niece, KL | 1 |
| Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E | 1 |
| Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M | 1 |
| Akyuz, F; Baran, B; Besisik, F; Demir, K; Emrence, Z; Evirgen, S; Gokturk, S; Karaca, C; Kaymakoglu, S; Ormeci, A; Soyer, OM; Ustek, D | 1 |
| Goda, Y; Izutsu, K; Shibata, H; Yoshida, H | 1 |
| Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J | 1 |
| Jiang, L; Lin, L; Wang, M; Wang, Y; Ye, B | 1 |
| Chen, L; Chen, Y; Li, B | 1 |
| Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X | 1 |
| Caballero-Salazar, S; De la Mora-De la Mora, I; Enríquez-Flores, S; García-Torres, I; Hernández-Alcántara, G; López-Velázquez, G; Molina-Ortiz, D; Nava, G; Olivos-García, A | 1 |
| Hatakeyama, S; Hosogoe, S; Imanishi, K; Ohyama, C; Okamoto, T; Saitoh, F; Suzuki, T; Takashima, T; Tanaka, Y | 1 |
| Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Amatya, GL; Gurung, SB; Gyawali, P; Kc, SR | 1 |
| Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME | 1 |
| Joshi, AA; Nerkar, PP | 1 |
| Huang, X; Liu, Y; Shen, Y; Su, YW; Sun, LN; Wang, YQ; Yang, YQ; Ying, YW; Zhang, XH; Zhang, Y | 1 |
| Arnaud, B; Arnoult, C; Escoffier, J; Hograindleur, JP; Kaba, M; Le Blévec, E; Martinez, G; Nef, S; Ray, PF; Stévant, I | 1 |
| Abad-Santos, F; Cabaleiro, T; Mejía, G; Ochoa, D; Román, M; Saiz-Rodríguez, M | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Fukuda, K; Fukuda, M; Hirashita, Y; Kawahara, Y; Kodama, M; Kudo, Y; Matsunari, O; Mizukami, K; Murakami, K; Ogawa, R; Okamoto, K; Okimoto, T; Wada, Y | 1 |
| Hancu, G; Kelemen, H; Papp, LA; Tóth, G | 1 |
| de la Mora-de la Mora, I; de Vos, P; Enríquez-Flores, S; Fernández-Lainez, C; Flores-López, LA; García-Torres, I; Gutiérrez-Castrellón, P; López-Velázquez, G; Matadamas-Martínez, F; Yépez-Mulia, L | 1 |
| Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y | 1 |
| Birangal, S; Farooqui, J; Fatima, F; Jagadish, PC; Patil, PH; Pinjari, J; Rao, M; Rastogi, H; Sharma, T; Shenoy, GG | 1 |
| Alabanza, A; Lohmer, L; Patel, J; Schueller, O; Singh, N; Willson, A | 1 |
| Cheng, X; Han, T; Jin, R; Li, J; Li, K | 1 |
| Chen, P; Fan, K; Luo, P; Peng, J; Wang, X; Zhang, Z; Zhu, X | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Barberio, B; Black, CJ; de Bortoli, N; Ford, AC; Savarino, E; Visaggi, P | 1 |
| Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H | 1 |
| Aktan, Ç; Balcan, E; Buran, T; Kasap, E; Korkmaz, M; Solmaz Hasdemir, P; Toraman Avcu, A | 1 |
| Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Sugiyama, A; Takei, Y | 1 |
| Afzal, NA; Andrews, E; Beattie, RM; Hayen, A; Liddicoat, I; Tighe, MP | 1 |
| López-Suárez, CM | 1 |
| Abdo-Francis, JM | 1 |
93 review(s) available for omeprazole and rabeprazole
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments in anti-Trichomonas research: An update review.
Topics: Antiparasitic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trichomonas; Trichomonas Infections | 2018 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
[H+, K+ -ATPase, H+ -ATPase].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amino Acids; Animals; Benzimidazoles; Binding Sites; H(+)-K(+)-Exchanging ATPase; Humans; Omeprazole; Proteins; Proton Pump Inhibitors; Rabeprazole; Stomach | 1996 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Helicobacter Infections; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 1998 |
Review article: the pharmacology of rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1999 |
Review article: the pharmacokinetics of rabeprazole in health and disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Disease; Enzyme Inhibitors; Health; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1999 |
Review article: drug interactions with agents used to treat acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Enzyme Inhibitors; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1999 |
Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1999 |
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Rabeprazole | 1999 |
Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Enterochromaffin-like Cells; Enzyme Inhibitors; Gastrins; Humans; Hyperplasia; Omeprazole; Rabeprazole | 1999 |
Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Humans; Omeprazole; Rabeprazole | 1999 |
Review article: rabeprazole's tolerability profile in clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Omeprazole; Rabeprazole; Randomized Controlled Trials as Topic | 1999 |
Review article: rabeprazole's profile in patients with gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastrointestinal Diseases; Humans; Omeprazole; Rabeprazole; Randomized Controlled Trials as Topic | 1999 |
[Two cases of ocular damage associated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Vision Disorders | 2000 |
The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Controlled Clinical Trials as Topic; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Prognosis; Rabeprazole; Risk Assessment; Stomach Ulcer; Treatment Outcome | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2000 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2001 |
Efficacy of rabeprazole once daily for acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Stomach Ulcer | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Duodenal Ulcer; Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach Ulcer; Sulfoxides | 2001 |
Proton pump inhibitors and their drug interactions: an evidence-based approach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Gastrointestinal Agents; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Genotype; Humans; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
[A new blocker of proton pump pariet: pharmacological properties and effectiveness of clinical application].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Bacterial Infections; Benzimidazoles; Enzyme Inhibitors; Humans; Injections, Intravenous; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Randomized Controlled Trials as Topic; Ranitidine; Sulfoxides; Treatment Outcome | 2001 |
[Pariet in current patterns of eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
[Safety profile of pariet clinical use (a literature review)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Drug Interactions; Enzyme Inhibitors; Gastric Mucosa; Gastrins; Humans; Neoplasms; Omeprazole; Proton-Translocating ATPases; Rabeprazole | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Duodenal Ulcer; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Stomach Ulcer; Sulfoxides | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Costs; Drug Interactions; Duodenal Ulcer; Gastrins; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Rabeprazole; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Stomach Ulcer; Zollinger-Ellison Syndrome | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Omeprazole; Rabeprazole; Treatment Failure | 2002 |
[Continuation of acid suppression therapy after H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esophagitis, Peptic; Feasibility Studies; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2002 |
[Proton pump inhibitors: Rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Depression, Chemical; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2002 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Esophagitis, Peptic; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Ranitidine | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aging; Anti-Ulcer Agents; Benzimidazoles; Biological Availability; Child; Clinical Trials as Topic; Drug Interactions; Female; Food-Drug Interactions; Humans; Intestinal Absorption; Male; Omeprazole; Rabeprazole | 2002 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Rabeprazole; Treatment Outcome | 2003 |
Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Omeprazole; Placebo Effect; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Esomeprazole; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
[Modern approach to the therapy of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole; Treatment Outcome | 2003 |
Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Interactions; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Esomeprazole; Gastric Acid; Humans; Liver; Metabolic Clearance Rate; Omeprazole; Parietal Cells, Gastric; Patient Selection; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Time Factors; Treatment Outcome | 2004 |
Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Interactions; Gastroesophageal Reflux; Humans; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Safety | 2004 |
[Primary care for GEDR].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Circadian Rhythm; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Laparoscopy; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Markov Chains; Meta-Analysis as Topic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic | 2004 |
[PPI: new strategies for GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Depression, Chemical; Drug Resistance; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Homozygote; Humans; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Peptic Ulcer; Rabeprazole | 2004 |
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Wound Healing | 2004 |
[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Rabeprazole | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesophageal Reflux; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Benzimidazoles; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Korea; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2005 |
CYP2C19 genotype and the PPIs--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2005 |
[Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; National Health Programs; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2005 |
[Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
[Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive System; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome | 2006 |
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Genotype; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2006 |
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis | 2006 |
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2006 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2007 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Rabeprazole | 2007 |
Recent advances in chirally pure proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Isomerism; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Stereoselective disposition of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2008 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Controlled Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Lansoprazole; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Duodenal Ulcer; Dyspepsia; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Stomach Ulcer | 2000 |
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing | 2010 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Omeprazole; Pain Measurement; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esophagus; Disease Progression; Esophageal Neoplasms; Gastroesophageal Reflux; Humans; Immunologic Factors; Lansoprazole; Neutrophils; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2013 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.
Topics: Anti-Ulcer Agents; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2016 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Determination of Proton Pump Inhibitors by Spectrophotometric, Chromatographic and by Hyphenated Techniques: A Review.
Topics: Chromatography, Liquid; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tandem Mass Spectrometry | 2021 |
Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electrophoresis; Esomeprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2021 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointestinal Agents; Heartburn; Humans; Network Meta-Analysis; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
Pharmacological treatment of gastro-oesophageal reflux in children.
Topics: Adolescent; Child; Esomeprazole; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine | 2023 |
207 trial(s) available for omeprazole and rabeprazole
| Article | Year |
|---|---|
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 1995 |
Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cross-Over Studies; Humans; Hydroxylation; Japan; Male; Mephenytoin; Omeprazole; Phenotype; Proton Pump Inhibitors; Rabeprazole; Reference Values; Smoking | 1995 |
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Diazepam; Drug Interactions; Half-Life; Humans; Hydroxylation; Male; Mephenytoin; Mixed Function Oxygenases; Nordazepam; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Reference Values; Single-Blind Method | 1995 |
Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Analysis of Variance; Benzimidazoles; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Evaluation; Fasting; Food; Half-Life; Humans; Japan; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1994 |
Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Half-Life; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry, Ultraviolet | 1994 |
Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa; Gastrins; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1997 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastrins; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Stomach Ulcer; Treatment Outcome | 1998 |
An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Gastric Acid; Gastrins; Half-Life; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1998 |
Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Female; Gastroscopy; Humans; Male; Middle Aged; Omeprazole; Pain; Rabeprazole; Stomach Ulcer; Treatment Outcome | 1998 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton-Translocating ATPases; Rabeprazole; Time Factors; Treatment Outcome | 1998 |
A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Gastric Acidity Determination; Gastric Mucosa; Gastrins; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Rabeprazole; Radioimmunoassay; Statistics, Nonparametric | 1998 |
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Endoscopy, Gastrointestinal; Europe; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 1999 |
Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Stomach | 1998 |
Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Duodenal Ulcer; Female; Gastrins; Humans; Male; Middle Aged; Omeprazole; Rabeprazole | 1999 |
Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Half-Life; Humans; Male; Omeprazole; Proton-Translocating ATPases; Rabeprazole | 1999 |
Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chronic Disease; Enzyme Inhibitors; Humans; Liver Cirrhosis; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Single-Blind Method | 1999 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 1999 |
The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Endocrine Glands; Gastric Acid; Gastric Juice; Gastric Mucosa; Hormones; Humans; Hydrocortisone; Hydrogen-Ion Concentration; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Reference Values; Testosterone | 1999 |
Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Blood Cells; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Electrocardiography; Enzyme Inhibitors; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Renal Dialysis; Renal Insufficiency; Time Factors | 1999 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2000 |
A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Elective Surgical Procedures; Female; Gastric Juice; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pneumonia, Aspiration; Prospective Studies; Rabeprazole; Ranitidine | 2000 |
Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Female; Humans; Male; Middle Aged; Omeprazole; Pain Measurement; Rabeprazole; Ranitidine; Treatment Outcome | 2000 |
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Europe; Female; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Recurrence; Stomach Ulcer; Treatment Outcome | 2000 |
A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Gastric Acid; Gastric Acidity Determination; Gastrins; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Rabeprazole; Stomach Ulcer; Treatment Outcome | 2000 |
Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptones; Rabeprazole | 2000 |
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome | 2000 |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Rabeprazole; Treatment Outcome | 2000 |
Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Benzimidazoles; Double-Blind Method; Female; Gastrins; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Treatment Outcome | 2000 |
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Esophagoscopy; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Probability; Rabeprazole; Secondary Prevention; Statistics, Nonparametric; Treatment Outcome | 2000 |
CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2000 |
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Tinidazole | 2000 |
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis, Peptic; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Recurrence; Safety; Time Factors | 2000 |
5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole | 2000 |
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Lactobacillus acidophilus; Male; Middle Aged; Omeprazole; Patient Compliance; Prospective Studies; Rabeprazole | 2000 |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus; Male; Omeprazole; Probiotics; Prospective Studies; Rabeprazole; Tinidazole; Treatment Outcome | 2001 |
Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2000 |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Rabeprazole; Treatment Outcome | 2001 |
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Gastric Acidity Determination; Gastrins; Genotype; Helicobacter Infections; Humans; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole | 2001 |
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2001 |
CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2001 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2001 |
[Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Famotidine; Gastric Juice; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Middle Aged; Monitoring, Physiologic; Omeprazole; Rabeprazole | 2001 |
Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Gastrins; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2001 |
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Double-Blind Method; Female; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Liver; Male; Mixed Function Oxygenases; Omeprazole; Proton-Translocating ATPases; Rabeprazole | 2001 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Diarrhea; Drug Resistance; Drug Therapy, Combination; Duodenal Ulcer; Exanthema; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Stomach Ulcer; Time Factors; Treatment Outcome | 2001 |
[Modern means of anti-Helicobacter therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Proton-Translocating ATPases; Rabeprazole | 2001 |
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Female; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2001 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Neutrophils; Omeprazole; Peroxidase; Proton Pump Inhibitors; Pyloric Antrum; Rabeprazole; Stomach Ulcer | 2002 |
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Health Surveys; Heartburn; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Quality of Life; Rabeprazole; Treatment Outcome | 2002 |
Integrated acidity and rabeprazole pharmacology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Rabeprazole; Treatment Outcome | 2002 |
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Treatment Outcome | 2002 |
A modification of the quininium resin test for assessing gastric acidity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Achlorhydria; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Fluorometry; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Quinine; Rabeprazole | 2002 |
[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Benzimidazoles; Dyspepsia; Enzyme Inhibitors; Esophagitis, Peptic; Humans; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2002 |
[Regeneration of the esophagus epitheliocytes. Evaluation of pariet efficacy in the treatment of patients with reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Epithelial Cells; Esophagitis, Peptic; Esophagus; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2002 |
[Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Apoptosis; Benzimidazoles; Duodenal Ulcer; Enzyme Inhibitors; Epithelial Cells; Gastric Mucosa; Helicobacter pylori; Humans; Omeprazole; Proton-Translocating ATPases; Rabeprazole | 2002 |
The efficacy of lafutidine in improving preoperative gastric fluid property: a comparison with ranitidine and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Female; Gastric Acid; Gastric Acidity Determination; Histamine H2 Antagonists; Humans; Intraoperative Complications; Intubation, Gastrointestinal; Male; Middle Aged; Omeprazole; Piperidines; Preoperative Care; Proton Pump Inhibitors; Pyridines; Rabeprazole; Ranitidine; Risk Assessment; Stomach | 2002 |
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Safety; Single-Blind Method; Treatment Outcome | 2002 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; DNA; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2002 |
Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Health Status Indicators; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quality of Life; Rabeprazole; Randomized Controlled Trials as Topic; Severity of Illness Index | 2002 |
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Peptic Ulcer; Rabeprazole; Statistics, Nonparametric; Treatment Outcome | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2002 |
[The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Double-Blind Method; Duodenal Ulcer; Humans; Middle Aged; Omeprazole; Rabeprazole | 2002 |
[Antisecretory effect of losec and pariet in peptic ulcer therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole | 2002 |
Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Patient Compliance; Prospective Studies; Proton-Translocating ATPases; Rabeprazole | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole | 2003 |
[Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; Epithelial Cells; Esophagitis, Peptic; Esophagus; Humans; Mucous Membrane; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2002 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure; Treatment Outcome | 2003 |
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastrins; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole; Recurrence; Treatment Outcome | 2003 |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Rifabutin; Treatment Outcome | 2003 |
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Cross-Over Studies; Female; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Rabeprazole; Urea | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Rabeprazole; Tinidazole; Treatment Outcome | 2003 |
Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Benzimidazoles; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gastric Acidity Determination; Gastric Mucins; Gastric Mucosa; Humans; Male; Middle Aged; Mucus; Omeprazole; Probability; Rabeprazole; Reference Values; Sensitivity and Specificity | 2003 |
Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Eating; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Postprandial Period; Rabeprazole; Time Factors | 2003 |
Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Sensitivity and Specificity | 2003 |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Safety | 2003 |
Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Outcome Assessment, Health Care; Patient Satisfaction; Proton-Translocating ATPases; Psychometrics; Rabeprazole; Randomized Controlled Trials as Topic; Sick Role | 2003 |
Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Gastric Acid; Gastric Acidity Determination; Humans; Male; Omeprazole; Postprandial Period; Rabeprazole; Treatment Outcome | 2003 |
Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Tinidazole; Treatment Outcome | 2003 |
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Antacids; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2003 |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome | 2003 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Benzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Gastrointestinal Diseases; Heartburn; Humans; Male; Middle Aged; Nausea; Omeprazole; Pain; Proton Pump Inhibitors; Rabeprazole | 2003 |
Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Female; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2003 |
Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Digoxin; Drug Interactions; Formularies, Hospital as Topic; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2003 |
Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Double-Blind Method; Gastric Acidity Determination; Gastric Mucosa; Heterozygote; Homozygote; Humans; Hydrogen-Ion Concentration; Male; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Stomach | 2003 |
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Benzimidazoles; Cholecystectomy; Duodenogastric Reflux; Dyspepsia; Female; Gastritis; Gastroscopy; Humans; Male; Middle Aged; Omeprazole; Pilot Projects; Rabeprazole; Statistics, Nonparametric; Sucralfate; Treatment Outcome | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole; Tinidazole; Treatment Outcome | 2003 |
[A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2003 |
[Combination therapy of chronic pancreatitis (double-blind, placebo-controlled, pilot studies)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Omeprazole; Pancreatitis; Pilot Projects; Proton-Translocating ATPases; Rabeprazole; Russia | 2003 |
Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Chronotherapy; Cross-Over Studies; Drug Therapy, Combination; Gastric Acid; Helicobacter pylori; Humans; Male; Monitoring, Ambulatory; Omeprazole; Rabeprazole; Ranitidine; Reference Values | 2003 |
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alkalies; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Rabeprazole; Sulfoxides | 2003 |
Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Rabeprazole | 2003 |
The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Esophagitis; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Postprandial Period; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2003 |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Rabeprazole; Treatment Outcome | 2003 |
Use of bovine lactoferrin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Breath Tests; Cattle; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Time Factors; Tinidazole | 2003 |
[Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chest Pain; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pumps; Rabeprazole; Treatment Outcome | 2003 |
[Comparative clinical and economic efficiency of new generation proton pump inhibitors in the treatment of gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Drug Administration Schedule; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Treatment Outcome | 2003 |
[The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastric Acidity Determination; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Multivariate Analysis; Omeprazole; Polymorphism, Genetic; Probability; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Statistics, Nonparametric; Treatment Outcome | 2003 |
Association between nocturnal bruxism and gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Bruxism; Electromyography; Female; Gastroesophageal Reflux; Humans; Male; Masticatory Muscles; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
The effect of eight weeks of rabeprazole therapy on nitric oxide plasma level and esophageal pH and motility and motility nitric oxide plasma level in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Esophagus; Female; Gastrointestinal Motility; Humans; Hydrogen-Ion Concentration; Male; Manometry; Middle Aged; Monitoring, Ambulatory; Nitric Oxide; Nitrites; Omeprazole; Rabeprazole; Time Factors | 2004 |
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Treatment Outcome | 2004 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Benzimidazoles; Clarithromycin; DNA; Drug Evaluation; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Polymerase Chain Reaction; Rabeprazole; Risk Factors; Smoking; Tinidazole; Treatment Outcome | 2004 |
Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2003 |
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; China; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole; Treatment Outcome | 2004 |
[Comparative efficacy of proton pump inhibitors in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acidity Determination; Gastric Juice; Gastroenteritis; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2003 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Costs; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole; Tinidazole; Treatment Outcome | 2004 |
Health-related quality of life in patients with cardiovascular disease--the effect of upper gastrointestinal symptom treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiovascular Diseases; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Omeprazole; Quality of Life; Rabeprazole | 2004 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Patient Compliance; Peptic Ulcer; Prospective Studies; Rabeprazole; Smoking; Tinidazole; Treatment Outcome | 2004 |
Bioequivalence study of rabeprazole sodium on healthy human volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Dose-Response Relationship, Drug; Humans; Male; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Therapeutic Equivalency | 2004 |
Seven-day therapy for Helicobacter pylori in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Treatment Outcome | 2004 |
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Middle Aged; Omeprazole; Quality of Life; Rabeprazole; Treatment Outcome | 2004 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Pilot Projects; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Salicylates; Tetracycline; Treatment Outcome | 2004 |
Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Tacrolimus | 2004 |
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Female; Follow-Up Studies; Gastroesophageal Reflux; Health Status; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Prospective Studies; Quality of Life; Rabeprazole; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2004 |
Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina Pectoris; Anti-Ulcer Agents; Benzimidazoles; Comorbidity; Coronary Artery Disease; Exercise Test; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Rabeprazole | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mexico; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Time Factors; Treatment Outcome | 2004 |
Significance of non-erosive minimal esophageal lesions in gastro-esophageal reflux disorder.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esophageal Diseases; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Korea; Male; Middle Aged; Omeprazole; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2004 |
[Prospective comparative study on protective effect of the proton pump inhibitor and the prostaglandin analog on H. pylori-negative gastric mucosa of healthy subjects against low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Benzimidazoles; Enzyme Inhibitors; Female; Gastric Mucosa; Gastroscopy; Humans; Male; Misoprostol; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2004 |
Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Chronic Disease; Female; Humans; Laryngitis; Male; Middle Aged; Omeprazole; Rabeprazole; Surveys and Questionnaires; Time Factors | 2004 |
[Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Benzimidazoles; Child; Enzyme Inhibitors; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Stomach | 2004 |
Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chronic Disease; Double-Blind Method; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Hypopharynx; Life Style; Male; Middle Aged; Omeprazole; Pharyngitis; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Female; Gastric Acid; Gastric Mucosa; Genotype; Humans; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton-Translocating ATPases; Rabeprazole; Stomach | 2004 |
Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Humans; Male; Omeprazole; Rabeprazole | 2004 |
[The effect of rabeprazole on gastric pH in patients with gastric ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Stomach Ulcer | 2004 |
[Some comparative aspects of treating the gastroesophageal reflux disease eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
[Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Esophagoscopy; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bacillus; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Probiotics; Prospective Studies; Rabeprazole | 2004 |
The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Polysomnography; Proton Pump Inhibitors; Rabeprazole; Sleep; Sleep Wake Disorders | 2005 |
Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Benzimidazoles; Biological Availability; Cross-Over Studies; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Omeprazole; Rabeprazole | 2005 |
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedures; Diterpenes; Endoscopy, Gastrointestinal; Gastritis; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Incidence; Omeprazole; Postoperative Complications; Premedication; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Ulcer; Upper Gastrointestinal Tract | 2005 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Biomarkers; Drug Therapy, Combination; Duodenal Ulcer; Endothelin-1; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Omeprazole; Rabeprazole | 2005 |
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Chalcone; Chalcones; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole | 2005 |
One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Clarithromycin; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole; Treatment Outcome; Urea | 2005 |
Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Rabeprazole; Secondary Prevention; Treatment Outcome | 2005 |
[Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenoscopy; Esophagoscopy; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2005 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastric Mucosa; Gastrins; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Male; Metaplasia; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Severity of Illness Index | 2005 |
Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disorders; Esophagus; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Pain; Prospective Studies; Rabeprazole; Treatment Outcome | 2005 |
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Female; Gastric Acid; Genotype; Histamine H2 Antagonists; Humans; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton-Translocating ATPases; Rabeprazole | 2005 |
[A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Ranitidine | 2005 |
Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Barrett Esophagus; Benzimidazoles; Esophageal pH Monitoring; Esophagus; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Proton-Translocating ATPases; Quality of Life; Rabeprazole; Treatment Outcome | 2005 |
[The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2005 |
[Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2005 |
The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cardia; Double-Blind Method; Esophagogastric Junction; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Postprandial Period; Rabeprazole | 2005 |
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Administration, Oral; Adult; Benzimidazoles; Cross-Over Studies; Drug Administration Schedule; Gastric Acid; Gastric Acidity Determination; Heartburn; Humans; Hydrogen-Ion Concentration; Male; Monitoring, Physiologic; Omeprazole; Piperidines; Postprandial Period; Pyridines; Rabeprazole; Reference Values; Risk Assessment; Time Factors; Treatment Outcome | 2005 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prevalence; Proton-Translocating ATPases; Pyloric Antrum; Rabeprazole; Retrospective Studies; Treatment Outcome | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Patient Compliance; Peptic Ulcer; Prospective Studies; Rabeprazole; Treatment Outcome | 2005 |
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Dexlansoprazole; Humans; Immunosuppressive Agents; Kidney Transplantation; Kinetics; Lansoprazole; Mixed Function Oxygenases; Models, Molecular; Molecular Structure; Omeprazole; Rabeprazole; Stereoisomerism; Substrate Specificity; Tacrolimus | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Heartburn; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Rabeprazole; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Monitoring, Physiologic; Omeprazole; Rabeprazole | 2005 |
Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aminopyrine; Anti-Bacterial Agents; Anti-Infective Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Liver; Liver Function Tests; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2005 |
Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Benzimidazoles; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Male; Omeprazole; Rabeprazole; Reproducibility of Results; Sulfides | 2005 |
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis, Peptic; Female; Gastrins; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Treatment Outcome | 2005 |
A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole; Stomach Ulcer; Treatment Outcome | 2005 |
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chest Pain; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Sensitivity and Specificity | 2005 |
Dual effects of rabeprazole on solid-phase gastric emptying assessed by the 13C-octanoate breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Caprylates; Carbon Isotopes; Cross-Over Studies; Female; Gastric Emptying; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Regression Analysis | 2005 |
Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; Esophageal pH Monitoring; Esophagus; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2005 |
Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disorders; Esophagitis, Peptic; Esophagoscopy; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Severity of Illness Index; Treatment Outcome | 2005 |
Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Benzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Rabeprazole | 2005 |
The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Famotidine; Female; Follow-Up Studies; Gastric Acidity Determination; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Pilot Projects; Proton Pump Inhibitors; Rabeprazole; Stomach; Treatment Outcome | 2004 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomonal Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Time Factors; Tinidazole; Treatment Outcome | 2006 |
Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; China; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2006 |
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Gastric Acidity Determination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Rabeprazole | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Point Mutation; Rabeprazole; Treatment Outcome | 2006 |
[A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine | 2006 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Minocycline; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2006 |
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Enzyme Inhibitors; Female; Fluvoxamine; Heterozygote; Homozygote; Humans; Male; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Selective Serotonin Reuptake Inhibitors | 2006 |
Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Physicians, Family; Rabeprazole; Sensitivity and Specificity | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Tinidazole; Treatment Outcome | 2006 |
Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Benzimidazoles; Breath Tests; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole; Smoking; Treatment Outcome; Urease | 2006 |
Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Female; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Rabeprazole; Treatment Outcome | 2006 |
Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Benzimidazoles; China; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Gastrins; Genotype; Humans; Hydrogen-Ion Concentration; Male; Metabolism; Mixed Function Oxygenases; Omeprazole; Polymorphism, Restriction Fragment Length; Rabeprazole; Stomach | 2006 |
Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Patient Satisfaction; Quality of Life; Rabeprazole | 2006 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Surveys and Questionnaires; Treatment Outcome | 2007 |
[Rabeprazole test and comparison of the effectiveness of course treatment with rabeprazole in patients with gastroesophageal reflux disease and non-coronary chest pain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Prevalence; Rabeprazole; Severity of Illness Index | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Retreatment; Stomach Diseases; Treatment Outcome | 2007 |
Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagitis; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2007 |
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Endoscopy; Female; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Stomach Ulcer; Treatment Outcome | 2008 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2008 |
A glass of water immediately increases gastric pH in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Esomeprazole; Female; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach; Time Factors; Water | 2008 |
Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Critical Illness; Double-Blind Method; Esomeprazole; Female; Gastric Acidity Determination; Gastric Juice; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2008 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administration Schedule; Duodenal Ulcer; Duodenoscopy; Female; Gastric Acidity Determination; Gastroscopy; Hemostatic Techniques; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Rabeprazole; Recurrence; Stomach Ulcer; Time Factors; Treatment Outcome; Young Adult | 2009 |
Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Young Adult | 2010 |
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabeprazole; Ticlopidine; Treatment Outcome | 2010 |
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Omeprazole; Peptic Ulcer; Polymorphism, Single Nucleotide; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Young Adult | 2010 |
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Obesity; Omeprazole; Overweight; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Treatment Outcome; Wound Healing | 2011 |
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Topics: Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Japan; Lansoprazole; Male; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2013 |
Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Microfilament Proteins; Omeprazole; Paris; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ticlopidine | 2013 |
A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
Topics: Adult; Aged; Cytochrome P-450 CYP2C19; Esophagitis, Peptic; Female; Humans; Japan; Male; Middle Aged; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2014 |
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
Topics: Adult; Asian People; Cytochrome P-450 CYP2C19; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2014 |
Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.
Topics: Adult; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Obesity; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach; Young Adult | 2014 |
Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Anxiety; Cytochrome P-450 CYP2C19; Depression; Dose-Response Relationship, Drug; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Genotype; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Severity of Illness Index; Smoking; Young Adult | 2015 |
In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Dabigatran; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Thrombin; Young Adult | 2015 |
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult | 2015 |
Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Cross-Sectional Studies; Drug Therapy, Combination; Feces; Female; Gastroesophageal Reflux; Helicobacter Infections; Humans; Male; Middle Aged; Nepal; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2020 |
Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Topics: Adult; Anti-Ulcer Agents; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dietary Fats; Fasting; Female; Food-Drug Interactions; Genotype; Humans; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2020 |
A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
Topics: Acetamides; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Humans; Itraconazole; Omeprazole; Protein Kinases; Proton Pump Inhibitors; Rabeprazole; Rifampin | 2022 |
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Topics: Amoxicillin; Anti-Ulcer Agents; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
218 other study(ies) available for omeprazole and rabeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Antiprotozoal activity of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antiprotozoal Agents; Drug Design; Entamoeba histolytica; Giardia lamblia; Humans; Lansoprazole; Omeprazole; Pantoprazole; Parasitic Diseases; Proton Pump Inhibitors; Rabeprazole; Trichomonas vaginalis | 2011 |
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Molecular Structure; N-Glycosyl Hydrolases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship; Trichomonas vaginalis | 2014 |
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Repositioning; Fatty Acid Synthases; Humans; Hydrogen-Ion Concentration; Lansoprazole; Palmitic Acid; Palmitoyl-CoA Hydrolase; Protein Structure, Tertiary; Proton Pump Inhibitors | 2015 |
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Genetic Diseases, Inborn; Humans; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Molecular Structure; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Small Molecule Libraries; Structure-Activity Relationship | 2017 |
Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
Topics: Azoles; Biocatalysis; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Insulysin; Isoindoles; Molecular Structure; Organoselenium Compounds; Structure-Activity Relationship | 2019 |
Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone-Lysine N-Methyltransferase; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Molecular Structure; Myeloid-Lymphoid Leukemia Protein; Protein Binding; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship | 2020 |
[Discovery and development of the proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benzimidazoles; Depression, Chemical; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Lansoprazole; Microsomes; Omeprazole; Rabeprazole | 1992 |
[Changes in the rat stomach after long-term administration of proton pump inhibitors (AG-1749 and E-3810)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastric Acid; Gastrins; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Male; Omeprazole; Parietal Cells, Gastric; Rabeprazole; Rats; Rats, Inbred Strains; Stomach; Vacuoles | 1992 |
New fluorescent probes E3810 and methoxy E3810 for determining distributions of the apical membrane and the acidic compartment of gastric acid secreting cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Cell Membrane; Fluorescent Dyes; Gastric Acid; Gastric Mucosa; Guinea Pigs; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Omeprazole; Parietal Cells, Gastric; Rabbits; Rabeprazole; Salamandridae | 1992 |
Effects of histamine H2-receptor antagonists and a proton pump inhibitor on the mucosal hydroxyproline content of ethanol-HCl-induced gastric lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Collagen; Ethanol; Famotidine; Gastric Mucosa; Hydrochloric Acid; Hydroxyproline; Male; Omeprazole; Rabeprazole; Rats; Rats, Inbred Strains; Stomach Ulcer | 1992 |
Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Aminopyrine; Animals; Benzimidazoles; Bucladesine; Dogs; Dose-Response Relationship, Drug; Gastric Mucosa; Glutathione; H(+)-K(+)-Exchanging ATPase; Histamine; Male; Omeprazole; Parietal Cells, Gastric; Pentagastrin; Rabbits; Rabeprazole; Rana catesbeiana | 1991 |
Effects of two benzimidazoles as proton pump inhibitors on water immersion stress-induced gastric ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastric Mucosa; Immersion; Leukotrienes; Male; Omeprazole; Prostaglandins; Protons; Rabeprazole; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Psychological | 1991 |
The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Benzimidazoles; Glutathione; H(+)-K(+)-Exchanging ATPase; Hydrogen-Ion Concentration; Imidazoles; L-Lactate Dehydrogenase; Molecular Structure; NAD; Omeprazole; Pyruvate Kinase; Rabeprazole; Spectrophotometry; Stomach; Swine | 1990 |
A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Helicobacter pylori; Omeprazole; Proton Pumps; Rabeprazole | 1995 |
The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+,K(+)-ATPase.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Fluorescent Dyes; H(+)-K(+)-Exchanging ATPase; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach; Swine; Trypsin; Ultraviolet Rays | 1995 |
Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Cation Transport Proteins; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Male; Microsomes; Omeprazole; Potassium; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Wistar; Time Factors | 1994 |
Effect of antrectomy and drug-induced achlorhydria on urinary excretion of N-terminal big gastrin immunoreactivity in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Achlorhydria; Animals; Benzimidazoles; Female; Gastrectomy; Gastrins; Omeprazole; Peptide Fragments; Protein Precursors; Proton Pump Inhibitors; Pyloric Antrum; Rabeprazole; Rats; Rats, Sprague-Dawley | 1993 |
[Inhibitory action of E3810 on H+,K(+)-ATPase and gastric acid secretion in vitro].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Depression, Chemical; Dose-Response Relationship, Drug; Gastric Acid; In Vitro Techniques; Male; Omeprazole; Proton Pump Inhibitors; Rabbits; Rabeprazole; Swine | 1993 |
Different biochemical modes of action of two irreversible H+,K(+)-ATPase inhibitors, omeprazole and E3810.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Benzimidazoles; Binding Sites; Fluorescein-5-isothiocyanate; H(+)-K(+)-Exchanging ATPase; Hydrogen-Ion Concentration; In Vitro Techniques; Omeprazole; Potassium; Protein Conformation; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Stomach; Swine | 1993 |
Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Helicobacter pylori; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach; Urease | 1995 |
Mobilization of gastric histamine during repeated administration of a proton potassium adenosine triphosphatase inhibitor in intact and antrectomized rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Cell Count; Enzyme Inhibitors; Female; Gastric Mucosa; Gastrins; Histamine; Histamine Release; Histidine Decarboxylase; Hormones; Injections, Subcutaneous; Omeprazole; Parietal Cells, Gastric; Protein Precursors; Pyloric Antrum; Rabeprazole; Random Allocation; Rats; Rats, Sprague-Dawley | 1995 |
Oligomeric regulation of gastric H+,K+-ATPase.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Benzimidazoles; Binding Sites; Cell Fractionation; Cell Membrane; Enzyme Inhibitors; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Kinetics; Macromolecular Substances; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Swine | 1996 |
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Coumarins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Kinetics; Liver; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Proton-Translocating ATPases; Rabbits; Rabeprazole; Recombinant Proteins; Sulfaphenazole; Theophylline | 1996 |
Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Helicobacter pylori; Kinetics; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Urease | 1996 |
Plasma direct injection high-performance liquid chromatographic method for simultaneously determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated column.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Calibration; Chromatography, High Pressure Liquid; Dogs; Flavoproteins; Omeprazole; Rabeprazole; Stereoisomerism | 1996 |
Mechanism of inhibition of H+, K(+)-ATPase by sodium 2-[[4-(3- methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; beta-Cyclodextrins; Chromatography, High Pressure Liquid; Cyclodextrins; Enzyme Inhibitors; Glutathione; H(+)-K(+)-Exchanging ATPase; Mercaptoethanol; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Sulfhydryl Compounds | 1996 |
Enantioselective high-performance liquid chromatographic assay for determination of the enantiomers of a new anti-ulcer agent, E3810, in beagle dog plasma and rat plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Dogs; Enzyme Inhibitors; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Rats; Reproducibility of Results; Stereoisomerism | 1995 |
Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; beta-Naphthoflavone; Cell Line; Cytochrome P-450 CYP1A1; Enzyme Activation; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; RNA, Messenger; Sulfoxides | 1997 |
Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amino Acid Sequence; Animals; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Indicators and Reagents; Lansoprazole; Molecular Sequence Data; Omeprazole; Oxidoreductases; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sequence Homology, Amino Acid; Sphingosine; Stomach; Sulfhydryl Compounds; Sulfoxides; Swine | 1997 |
Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Binding Sites; Enzyme Inhibitors; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Kinetics; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship; Sulfoxides; Valinomycin | 1997 |
Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylglucosaminidase; Animals; Benzimidazoles; beta-Galactosidase; Bile; Chloroquine; Enzyme Inhibitors; Gastric Mucosa; Lipids; Liver; Lysosomes; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Sprague-Dawley | 1998 |
["Changing of the guard" in the inhibition of proton pumps?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1998 |
[Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole; Stomach Ulcer | 1998 |
Bile reflux due to disturbed gastric movement is a cause of spontaneous gastric ulcer in W/Wv mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Anti-Ulcer Agents; Benzimidazoles; Bile Acids and Salts; Bile Reflux; Diterpenes; Drug Evaluation, Preclinical; Gastric Mucosa; Gastrointestinal Motility; Hydrogen-Ion Concentration; Injections, Subcutaneous; Male; Mice; Mice, Mutant Strains; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach; Stomach Ulcer | 1999 |
Rabeprazole: pharmacology, pharmacokinetics, and potential for drug interactions. Introduction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1999 |
Rabeprazole is latest entrant in proton-pump-inhibitor class.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 1999 |
Rabeprazole sodium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole | 1999 |
In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2000 |
Effect of rabeprazole on histamine synthesis in enterochromaffin-like cells of mast cell-deficient (Ws/Ws) rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cell Division; Enterochromaffin Cells; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Gastrins; Histamine; Histidine Decarboxylase; Male; Mast Cells; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Wistar | 2000 |
Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastric Mucosa; Indomethacin; Injections, Intraperitoneal; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Omeprazole; Prostaglandins; Rabeprazole; Rats; Rats, Wistar; Stomach Ulcer | 2000 |
Helicobacter pylori infection influences nocturnal gastric acid breakthrough.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Gastric Acid; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Rabeprazole | 2000 |
[In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Child, Preschool; Enzyme Inhibitors; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pumps; Rabeprazole; Sulfides | 2000 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Drug Interactions; Duodenal Ulcer; Fees, Pharmaceutical; Gastroesophageal Reflux; Headache; Humans; Omeprazole; Proton-Translocating ATPases; Rabeprazole | 1999 |
A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cell Division; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Sulfides; Temperature | 2000 |
Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence | 2000 |
Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Trees; Drug Costs; Drugs, Generic; Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Health Care Costs; Histamine H2 Antagonists; Humans; Managed Care Programs; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine; United States | 2000 |
Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2000 |
Treatment strategies for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Interactions; Gastroesophageal Reflux; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2000 |
Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Humans; Hydrogen Peroxide; Lansoprazole; Neutrophils; Omeprazole; Phagocytosis; Pirenzepine; Rabeprazole; Superoxides | 2001 |
4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Pilot Projects; Rabeprazole | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngeal Diseases; Laryngoscopy; Male; Middle Aged; Omeprazole; Pharyngeal Diseases; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2001 |
Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cell Division; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Movement; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Sulfides; Treatment Failure | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence; Retrospective Studies; Treatment Failure | 2001 |
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alleles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Penicillins; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2001 |
Acute fulminant hepatitis after treatment with rabeprazole and terbinafine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifungal Agents; Benzimidazoles; Chemical and Drug Induced Liver Injury, Chronic; Humans; Male; Middle Aged; Naphthalenes; Omeprazole; Rabeprazole; Terbinafine | 2001 |
Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
Duodenal mucosa-associated lymphoid tissue lymphoma treated by eradication of Helicobacter pylori: report of 2 cases including EUS findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Benzimidazoles; Biopsy, Needle; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Duodenoscopy; Endosonography; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Treatment Outcome | 2001 |
Optimizing acid-suppression therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duodenal Ulcer; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Neoplasms; United States | 2001 |
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2002 |
Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Exons; Female; Humans; Immunosuppressive Agents; Lansoprazole; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Acute fulminant hepatitis after treatment with rabeprazole and terbinafine: is rabeprazole the culprit?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Benzimidazoles; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Drug Interactions; Follow-Up Studies; Humans; Naphthalenes; Omeprazole; Rabeprazole; Risk Assessment; Severity of Illness Index; Terbinafine | 2002 |
Helicobacter pylori eradication: do we have another ace up our sleeve?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Benzimidazoles; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Ofloxacin; Omeprazole; Rabeprazole | 2001 |
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pumps; Rabeprazole; Stomach Ulcer | 2002 |
The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Enterochromaffin-like Cells; Gastrins; Histamine; Male; Models, Animal; Omeprazole; Parietal Cells, Gastric; Rabeprazole; Rats; Rats, Wistar; Stomach | 2002 |
Rabeprazole: quest for the best PPI.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Enterochromaffin Cells; Gastrins; Humans; Omeprazole; Parietal Cells, Gastric; Rabeprazole; Rats | 2002 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Famotidine; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Hyperparathyroidism; Male; Omeprazole; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Rabeprazole | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Child; Child, Preschool; Drug Costs; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2002 |
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2002 |
[Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Rabeprazole | 2002 |
[Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Stomach Ulcer | 2002 |
[Pariet in eradication therapy plans].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Rabeprazole; Stomach Ulcer | 2002 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Peptic Ulcer; Rabeprazole; Tinidazole | 2002 |
Restoration of acid secretion following treatment with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Dithiothreitol; Enzyme Activation; Enzyme Inhibitors; Gastric Acid; Glutathione; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Sprague-Dawley; Stomach | 2002 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunologic Tests; Male; Middle Aged; Omeprazole; Pepsinogen A; Peptic Ulcer; Rabeprazole; Reagent Kits, Diagnostic; ROC Curve; Sensitivity and Specificity | 2002 |
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Interactions; Famotidine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Health Status Indicators; Humans; Male; Middle Aged; Omeprazole; Quality of Life; Rabeprazole | 2002 |
[A case of the successful treatment of the esophageal leukoplakia with rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Esophageal Neoplasms; Esophagitis, Peptic; Humans; Leukoplakia; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2002 |
Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Enzyme Inhibitors; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry, Ultraviolet | 2003 |
Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Antibodies; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2003 |
[Clinical aspects of using pariet in treating chronic pancreatitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chronic Disease; Enzyme Inhibitors; Humans; Omeprazole; Pancreatitis; Proton-Translocating ATPases; Quality of Life; Rabeprazole | 2002 |
Effects of rabeprazole sodium on gastric emptying, electrogastrography, and fullness.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Electrophysiology; Gastric Emptying; Gastrointestinal Motility; Humans; Male; Myoelectric Complex, Migrating; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Satiation | 2003 |
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Gene Expression Regulation; Humans; Hypericum; Lansoprazole; Omeprazole; Pantoprazole; Plant Preparations; Rabeprazole; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfoxides | 2003 |
A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Asthma; Benzimidazoles; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton-Translocating ATPases; Pulmonary Ventilation; Rabeprazole; Respiratory Function Tests | 2003 |
Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Animals; Anti-Ulcer Agents; Benzimidazoles; Disease Models, Animal; Gastric Mucosa; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Inflammation; Leukocytes; Male; Omeprazole; Rabeprazole | 2003 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Glossitis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome; Urea | 2003 |
Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Academic Medical Centers; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Breath Tests; Cytochrome P-450 CYP2C19; Female; Gastrins; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Inactivation, Metabolic; Male; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Taiwan; Time Factors | 2003 |
[Medico-economic efficacy of eradication schemes in helicobacter infections in patients with duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Benzimidazoles; Cost of Illness; Duodenal Ulcer; Female; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Rabeprazole | 2003 |
A new furoxan NO-donor rabeprazole derivative and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Drug Design; Helicobacter pylori; Indomethacin; Microbial Sensitivity Tests; Molecular Structure; Nitric Oxide Donors; Omeprazole; Oxadiazoles; Rabeprazole; Rats; Stomach Ulcer; Structure-Activity Relationship | 2003 |
Lactoferrin: milking ulcers?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cattle; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Omeprazole; Rabeprazole; Tinidazole | 2003 |
Direct effects of proton pump inhibitors on histamine release from rat enterochromaffin-like cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cells, Cultured; Dose-Response Relationship, Drug; Enterochromaffin-like Cells; Gastrins; Histamine Release; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Rats; Rats, Sprague-Dawley; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Proton-pump inhibitors in a Navy hospital after a formulary change.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Utilization Review; Economics, Pharmaceutical; Enzyme Inhibitors; Female; Formularies, Hospital as Topic; Hospitals, Military; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2003 |
Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Gastric Acid; Genotype; Helicobacter Infections; Helicobacter pylori; Homozygote; Humans; Hydrogen-Ion Concentration; Male; Mixed Function Oxygenases; Omeprazole; Rabeprazole | 2004 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2003 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Models, Economic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Blood Glucose; Breath Tests; Child; Child, Preschool; Clarithromycin; Diabetes Mellitus, Type 1; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Rabeprazole; Time Factors | 2004 |
Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Brain; Diagnosis, Differential; Gastroesophageal Reflux; Humans; Male; Mental Disorders; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Severity of Illness Index; Somatoform Disorders | 2003 |
Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; Esophagoscopy; Esophagus; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Manometry; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2004 |
Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antibodies; Antineoplastic Agents; Benzimidazoles; Cell Movement; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Chemokine CXCL2; Chemokines; Chemokines, CXC; Gastric Acid; Gastric Mucosa; Indomethacin; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Leukocytes; Macrophage Inflammatory Proteins; Male; Omeprazole; Rabeprazole; Rats; Rats, Wistar; Recurrence; RNA, Messenger; Specific Pathogen-Free Organisms; Stomach Ulcer; Tumor Necrosis Factor-alpha | 2004 |
Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Carbon; Chromatography, High Pressure Liquid; Dosage Forms; Electrodes; Hydrogen-Ion Concentration; Omeprazole; Oxidation-Reduction; Potentiometry; Rabeprazole; Reproducibility of Results; Sensitivity and Specificity; Tablets | 2004 |
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides | 2004 |
Chiral separation of omeprazole and several related benzimidazoles using supercritical fluid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohols; Amylose; Benzimidazoles; Chromatography; Lansoprazole; Models, Chemical; Omeprazole; Pantoprazole; Pressure; Rabeprazole; Stereoisomerism; Sulfoxides; Temperature; Time Factors | 2004 |
Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Transport; Caco-2 Cells; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorescent Dyes; HeLa Cells; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Rhodamine 123; Vinblastine | 2004 |
[Choice of proton pump inhibitors--does it play any role?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drugs, Generic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2004 |
Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Chromatography, High Pressure Liquid; Humans; Omeprazole; Rabeprazole; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Therapeutic Equivalency | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazole; Postprandial Period; Proton Pump Inhibitors; Rabeprazole; Random Allocation; Reference Values; Stomach | 2004 |
High-performance liquid chromatography method for the quantification of rabeprazole in human plasma using solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Humans; Omeprazole; Rabeprazole; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole; Tokyo | 2005 |
Spillover effects of restrictive drug formularies: a case study of PacifiCare in California.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; California; Formularies as Topic; Gatekeeping; Managed Care Programs; Omeprazole; Organizational Case Studies; Pantoprazole; Physician-Patient Relations; Rabeprazole; Sulfoxides | 2005 |
Bacteriostatic and bactericidal activity of rabeprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Dyspepsia; Female; Helicobacter pylori; Humans; In Vitro Techniques; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole | 2004 |
Rabeprazole-induced acute interstitial nephritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Acute Kidney Injury; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dyspepsia; Female; Humans; Middle Aged; Nephritis, Interstitial; Omeprazole; Rabeprazole | 2005 |
Proton pump inhibitors: a survey of prescribing in an Irish general hospital.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Female; Health Surveys; Hospitalization; Hospitals, General; Humans; Ireland; Male; Medical Audit; Middle Aged; Omeprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Rabeprazole | 2005 |
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Benzimidazoles; China; Cytochrome P-450 CYP2C19; Gastric Acidity Determination; Genotype; Humans; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole | 2005 |
Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Exocrine Glands; Female; Gastric Juice; Gastric Mucins; Humans; Male; Middle Aged; Mucus; Naproxen; Omeprazole; Proton-Translocating ATPases; Rabeprazole | 2005 |
[Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Female; Furazolidone; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; Middle Aged; Omeprazole; Organometallic Compounds; Rabeprazole; Time Factors | 2005 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Benzimidazoles; Drug Combinations; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Treatment Outcome | 2005 |
Attenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Allergens; Animals; Benzimidazoles; Bronchi; Bronchoalveolar Lavage Fluid; Capsaicin; Cimetidine; Cough; Dose-Response Relationship, Drug; Guinea Pigs; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; Hydrogen-Ion Concentration; Immunohistochemistry; Irritants; Omeprazole; Ovalbumin; Proton Pump Inhibitors; Rabeprazole; Trachea | 2005 |
Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Community Pharmacy Services; Cost-Benefit Analysis; Drug Costs; Enzyme Inhibitors; Health Care Surveys; Humans; Ireland; Lansoprazole; National Health Programs; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aerophagy; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Electric Impedance; Female; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Treatment Failure | 2005 |
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Benzimidazoles; Gastric Acid; Gastric Acidity Determination; Heartburn; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Omeprazole; Piperidines; Prognosis; Proton Pump Inhibitors; Pyridines; Rabeprazole; Severity of Illness Index; Treatment Outcome | 2005 |
Allergy to lansoprazole: study of cross-reactivity among proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross Reactions; Drug Hypersensitivity; Enzyme Inhibitors; Female; Humans; Immunoglobulin E; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Skin Tests | 2005 |
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Carbohydrate Sequence; Chromatography, High Pressure Liquid; Drug Stability; Humans; Models, Molecular; Molecular Sequence Data; Molecular Structure; Omeprazole; Rabeprazole; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2005 |
[Pharmacogenomical aspects of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole; Remission Induction; Time Factors | 2005 |
Effects of antisecretory agents on angiogenesis during healing of gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Base Sequence; Benzimidazoles; Biopsy, Needle; Case-Control Studies; Female; Gastric Mucosa; Gastroscopy; Humans; Immunohistochemistry; Male; Middle Aged; Molecular Sequence Data; Neovascularization, Physiologic; Nizatidine; Omeprazole; Polymerase Chain Reaction; Probability; Rabeprazole; Receptors, CXCR4; Reference Values; Risk Assessment; RNA, Messenger; Severity of Illness Index; Stomach Ulcer; Wound Healing | 2005 |
The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Drug Tolerance; Famotidine; Female; Gastric Acidity Determination; Gastrins; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Piperidines; Pneumonia, Aspiration; Preanesthetic Medication; Proton Pump Inhibitors; Rabeprazole | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom | 2005 |
Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Rabeprazole; Reproducibility of Results; Surveys and Questionnaires | 2005 |
Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Capsules; Esophageal pH Monitoring; Esophagus; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2005 |
Cryoablation of Barrett's esophagus: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; Cryosurgery; Esophagus; Humans; Male; Middle Aged; Omeprazole; Pilot Projects; Rabeprazole | 2005 |
[The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Quality of Life; Rabeprazole; Surveys and Questionnaires | 2005 |
Identification and synthesis of potential impurities of rabeprazole sodium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Contamination; Indicators and Reagents; Mass Spectrometry; Omeprazole; Rabeprazole; Spectrophotometry, Ultraviolet | 2005 |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Pilot Projects; Rabeprazole; Treatment Failure; Treatment Outcome | 2006 |
[Oral cavity manifestations of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagus; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Mouth; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Saliva; Severity of Illness Index; Stomatitis; Treatment Outcome | 2005 |
Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Cardiac Surgical Procedures; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroesophageal Reflux; Gastrointestinal Hemorrhage; Hernia, Hiatal; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Postoperative Care; Probability; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Risk Assessment; Treatment Outcome | 2006 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Gastrectomy; Gastric Mucosa; Gastric Stump; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Stomach Neoplasms | 2005 |
The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Catheterization; Esophagus; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach; Temperature | 2006 |
Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Female; Half-Life; Heterozygote; Homozygote; Humans; Male; Mixed Function Oxygenases; Omeprazole; Rabeprazole | 2006 |
"Best practice' for Helicobacter pylori eradication in the primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ireland; Omeprazole; Primary Health Care; Rabeprazole | 2006 |
Development and validation of a dissolution test for rabeprazole sodium in coated tablets.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Omeprazole; Rabeprazole; Reproducibility of Results; Sensitivity and Specificity; Solubility; Spectrophotometry, Ultraviolet; Tablets | 2006 |
Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross Reactions; Drug Hypersensitivity; Enzyme Inhibitors; Female; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Skin Tests | 2006 |
Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzimidazoles; Contraindications; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Rabeprazole; Ritonavir | 2006 |
A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; British Columbia; Cost Savings; Databases, Factual; Drug Utilization Review; Female; Health Services for the Aged; Hospitalization; Humans; Insurance, Pharmaceutical Services; Lansoprazole; Male; Omeprazole; Pantoprazole; Practice Patterns, Physicians'; Rabeprazole; Sulfoxides | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2006 |
Idiopathic pure red cell aplasia: case report with review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anemia; Benzimidazoles; Enzyme Inhibitors; Humans; Male; Omeprazole; Rabeprazole; Red-Cell Aplasia, Pure; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Canada; Costs and Cost Analysis; Drug Utilization Review; Health Benefit Plans, Employee; Humans; Insurance, Pharmaceutical Services; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2006 |
Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedures; Combined Modality Therapy; Esophagus; Famotidine; Female; Gastric Acid; Gastrointestinal Hemorrhage; Heart Diseases; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Perioperative Care; Rabeprazole; Stomach; Time Factors; Treatment Outcome | 2006 |
Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aminopyrine; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Case-Control Studies; Cytochrome P-450 Enzyme System; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Monitoring, Physiologic; Omeprazole; Rabeprazole; Treatment Outcome | 2006 |
Comparative drug effects: the case of GERD therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Disease Management; Gastroesophageal Reflux; Health Surveys; Histamine H2 Antagonists; Humans; Omeprazole; Outcome Assessment, Health Care; Patient Satisfaction; Product Surveillance, Postmarketing; Rabeprazole | 2007 |
Preparative chiral chromatography and chiroptical characterization of enantiomers of omeprazole and related benzimidazoles.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography; Chromatography, Supercritical Fluid; Circular Dichroism; Enzyme Inhibitors; Lansoprazole; Models, Chemical; Molecular Conformation; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2007 |
Pattern of proton pump inhibitor calls to Texas poison centers, 1998-2004.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Animals; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Poison Control Centers; Poisoning; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Texas | 2007 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Famotidine; Health Care Costs; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole; Organometallic Compounds; Peptic Ulcer; Rabeprazole; Ranitidine; Russia | 2007 |
[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Acidity Determination; Gastritis; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Muscarinic Antagonists; Omeprazole; Parietal Cells, Gastric; Pirenzepine; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Receptors, Histamine H2; Receptors, Muscarinic | 2007 |
Long-term proton pump inhibitor use in children: a retrospective review of safety.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Esophagitis; Female; Gastrins; Humans; Lansoprazole; Liver Function Tests; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Vitamin B 12 | 2008 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Ranitidine; Tetracycline; Treatment Failure | 2006 |
Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2007 |
Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Female; Fibrinolytic Agents; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Lebanon; Male; Middle Aged; Omeprazole; Prognosis; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Retrospective Studies; Risk Factors | 2008 |
Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Circadian Rhythm; Esophageal pH Monitoring; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazole; Predictive Value of Tests; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole | 2008 |
Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Sensitivity and Specificity; Sodium Bicarbonate | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
[Proton pump inhibition: more than only reflux therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Chest Pain; Clopidogrel; Comorbidity; Controlled Clinical Trials as Topic; Coronary Disease; Diagnosis, Differential; Drug Therapy, Combination; Gastroesophageal Reflux; Humans; Omeprazole; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine; Time Factors | 2008 |
Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Humans; Isoxazoles; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Zonisamide | 2009 |
Interaction between clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Lansoprazole; Myocardial Infarction; Odds Ratio; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine | 2009 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Schedule; Duodenal Ulcer; Duodenoscopy; Gastroscopy; Hemostatic Techniques; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Omeprazole; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Rabeprazole; Recurrence; Stomach Ulcer; Time Factors; Treatment Outcome | 2009 |
Long-term treatment with proton pump inhibitor is associated with undesired weight gain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Pressure; Body Mass Index; Body Weight; Case-Control Studies; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Weight Gain | 2009 |
Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Ticlopidine | 2010 |
Spectrophotometric determination of peptic ulcer sulfur-containing drugs in bulk form and in tablets.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Iodates; Limit of Detection; Omeprazole; Pantoprazole; Potassium Compounds; Powders; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry; Sulfur Compounds; Tablets | 2010 |
Enantioseparation of rabeprazole and omeprazole by nonaqueous capillary electrophoresis with an ephedrine-based ionic liquid as the chiral selector.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electrophoresis, Capillary; Ephedrine; Hydrogen Bonding; Ionic Liquids; Omeprazole; Rabeprazole; Stereoisomerism | 2010 |
Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Specimen Collection; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Monitoring; Fluvoxamine; Genotype; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2011 |
Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aminopyrine; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Breath Tests; Carbon Isotopes; Cytochrome P-450 CYP2C19; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2012 |
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biological Transport; Cell Line; Humans; Imidazoles; Immunoblotting; Inhibitory Concentration 50; Lansoprazole; Metformin; Omeprazole; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Protein Binding; Proton Pump Inhibitors; Rabeprazole | 2011 |
Comparison of the effects of omeprazole and rabeprazole on ticlopidine metabolism in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; In Vitro Techniques; Omeprazole; Platelet Aggregation Inhibitors; Rabeprazole; Ticlopidine | 2011 |
Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Asian People; Aspirin; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine H2 Antagonists; Humans; Male; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ticlopidine | 2012 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Carcinoma, Squamous Cell; Cytochrome P-450 CYP2C19; Drug Resistance; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophagectomy; Genotype; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Pharmacogenetics; Phenotype; Plastic Surgery Procedures; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer; Treatment Outcome; Wound Healing | 2013 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult | 2012 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Normal and polar-organic-phase high-performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro-methylated cellulose-based chiral stationary phase and determination of dexrabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2014 |
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Female; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Secretin; Sensitivity and Specificity; Stomach; Young Adult; Zollinger-Ellison Syndrome | 2013 |
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents | 2014 |
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Treatment Outcome | 2014 |
Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cytochrome P-450 CYP2C19; Female; Genetic Association Studies; Genotype; Humans; Inactivation, Metabolic; Male; Omeprazole; Pantoprazole; Polymorphism, Genetic; Rabeprazole | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Tokyo | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole | 2015 |
Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets.
Topics: Bicarbonates; Buffers; Drug Compounding; Humans; Hydrogen-Ion Concentration; Kinetics; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Solubility; Tablets, Enteric-Coated; Technology, Pharmaceutical | 2016 |
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors.
Topics: Electric Impedance; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2016 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan | 2017 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2018 |
First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.
Topics: Albendazole; Amino Acid Sequence; Encephalitozoon; Fungal Proteins; Gastrointestinal Diseases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Fungal; Humans; Microsporidia; Microsporidiosis; Omeprazole; Rabeprazole; Sequence Homology, Amino Acid; Thiamine; Triose-Phosphate Isomerase | 2018 |
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Topics: Aged; Aorta, Abdominal; Computed Tomography Angiography; Disease Progression; Esomeprazole; Female; Humans; Kidney Failure, Chronic; Lansoprazole; Logistic Models; Magnesium; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Renal Dialysis; Retrospective Studies; Vascular Calcification | 2018 |
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult | 2019 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry | 2020 |
Simultaneous enantioselective determination of omeprazole, rabeprazole, lansoprazole, and pantoprazole enantiomers in human plasma by chiral liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism; Tandem Mass Spectrometry | 2020 |
Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Fertilization; Humans; Lansoprazole; Male; Membrane Potentials; Middle Aged; Omeprazole; Pantoprazole; Phosphorylation; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Semen Analysis; Sperm Capacitation; Sperm Maturation; Sperm Motility; Spermatozoa; Young Adult | 2020 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
Multilevel Approach for the Treatment of Giardiasis by Targeting Arginine Deiminase.
Topics: Animals; Antiprotozoal Agents; Computer Simulation; Cysteine; Drug Evaluation, Preclinical; Drug Repositioning; Giardia lamblia; Giardiasis; Gold Sodium Thiomalate; Humans; Hydrolases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Thiamine; Trophozoites | 2021 |
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy.
Topics: Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Molecular Docking Simulation; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Reducing Agents | 2022 |
The influence of different proton pump inhibitors and potassium-competitive acid blockers on indomethacin-induced small intestinal injury.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; DNA, Ribosomal; Indomethacin; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Lipopolysaccharides; Mice; Omeprazole; Potassium; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides | 2022 |
Solvent-dependent carbon dots for multifunctional sensing of temperature, pH, and proton pump inhibitors.
Topics: Carbon; Esomeprazole; Hydrogen-Ion Concentration; Omeprazole; Phloroglucinol; Proton Pump Inhibitors; Quantum Dots; Rabeprazole; Solvents; Temperature | 2022 |
The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoplasmic Reticulum Stress; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2023 |
In vivo analysis of acute eletropharmacological effects of proton pump inhibitors using halothane-anesthetized dogs: a translational study of cardiovascular adverse events.
Topics: Animals; Dogs; Halothane; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2023 |
Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole | 2023 |
Reply to the letter to the editor "Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease".
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole | 2023 |